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Amanda C. Winters and Kathrin M. Bernt*
Division of Pediatric Hematology/Oncology/BMT, University of Colorado School of Medicine and Children’s Hospital 
Colorado, Aurora, CO, USA
The mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific 
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group 
of acute leukemias. More than 80 different partner genes in these fusions have been 
described, although the majority of leukemias result from MLL1 fusions with one of 
about six common partner genes. Approximately 10% of all leukemias harbor MLL1 
translocations. Of these, two patient populations comprise the majority of cases: patients 
younger than 1  year of age at diagnosis (primarily acute lymphoblastic leukemias) 
and young- to-middle-aged adults (primarily acute myeloid leukemias). A much rarer 
subgroup of patients with MLL1 rearrangements develop leukemia that is attributable 
to prior treatment with certain chemotherapeutic agents—so-called therapy-related 
leukemias. In general, outcomes for all of these patients remain poor when compared to 
patients with non-MLL1 rearranged leukemias. In this review, we will discuss the normal 
biological roles of MLL1 and its fusion partners, how these roles are hypothesized to be 
dysregulated in the context of MLL1 rearrangements, and the clinical manifestations of 
this group of leukemias. We will go on to discuss the progress in clinical management 
and promising new avenues of research, which may lead to more effective targeted 
therapies for affected patients.
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STRUCTURe AND FUNCTiON OF wiLD-TYPe MLL1
Mixed-Lineage Leukemia 1 (MLL1) Protein Structure and Binding 
Partners
The normal MLL1 gene at the 11q23 locus encodes an approximately 500-kDa nuclear protein 
with multiple functional domains and binding partners (Figure  1A), whose structure was first 
described by both Tkachuk et al. and Gu et al. (1, 2) and which is expressed in a wide variety of 
normal human tissues (3). The N-terminal portion of the protein contains a domain for binding 
Menin, a protein that serves as a link between MLL1 and the chromatin-binding protein lens 
epithelium-derived growth factor (LEDGF). LEDGF is a binder of dimethylated H3K36 (placed 
by ASH1L). The association of MLL1 with Menin/LEDGF is particularly critical for the function 
of MLL fusions, but also affects wild-type MLL1 (4–10). The N-terminus also contains AT-hook 
motifs (DNA-binding domains), speckled nuclear localization domains 1 and 2 (SNL-1 and SNL-2), 
and two repression domains (RD1 and RD2), the first of which (RD1) also contains a CxxC 
domain (1, 11–13). The CxxC domain has homology to DNA methyltransferase 1 (DNMT1), which 
FiGURe 1 | The structure of mixed-lineage leukemia (MLL) and normal vs aberrant MLL complexes. (A) The structure of the wild-type MLL protein, 
emphasizing the functional domains. MBD, Menin-binding domain; AT, AT hooks; SNL, speckled nuclear localization domains; RD, repression domains (black box in 
first RD represents the CXXC domain); BCR, breakpoint cluster region; PHD, PHD fingers; BD, bromodomain. CS1 and CS2 are the taspase-1 cleavage sites, and 
FYRN and FYRC are the domains whereby MLL-N and MLL-C interact after cleavage. TAD, transactivation domain; SET, H3K4 histone methyltransferase domain. 
(B) MLL fusion proteins are caused by chromosomal rearrangements leading to in-frame fusions between N-terminal MLL (to the BCR) and any of 80 different fusion 
partners. PHD domains, transactivation domains, and the SET domain are lost. (C) MLL-interacting proteins. Proteins involved in repressive functions of MLL are 
grouped above the MLL protein (regulated by CYP33), whereas proteins involved in activation of MLL-dependent transcription are grouped below the MLL protein 
schematic.
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methylates cytosine residues of DNA (11, 14). Although DNMT1 
preferentially targets hemimethylated CpG motifs, the MLL1 
CxxC domain binds non-methylated CpG DNA (15). All of 
these domains are typically conserved in chimeric MLL1 fusion 
proteins (12). The middle portion of MLL1 contains four plant 
homeodomain (PHD) fingers (which mediate protein–protein 
interactions) and a bromodomain (which mediates binding to 
histones with acetylated lysine residues). The C-terminal portion 
contains a transcriptional activation domain and a SET domain 
(1, 12, 16). The third PHD finger allows association between 
MLL1 and the cyclophilin CYP33, which is important for 
negative regulation of certain MLL1 target genes (17). The SET 
(Su(var)3-9, enhancer of zeste, trithorax) domain is homologous 
to that of Drosophila trithorax and catalyzes mono-, di-, and 
trimethylation of lysine 4 on histone 3 (H3K4) in vitro (1, 18). 
These latter four domains (PHD finger, bromodomain, activation 
domain, and SET domain) are all lost in most MLL1 fusion 
proteins (12) (Figure 1B).
After its translation, wild-type MLL1 is proteolytically 
cleaved by the enzyme taspase-1 (19, 20). The resulting 320-kDa 
N-terminal fragment (MLL-N) contains all domains except the 
transcriptional activation domain and the SET domain, both of 
which are retained by the 180-kDa C-terminal fragment (MLL-
C). MLL-N and MLL-C normally associate with one another as 
components of a multiprotein complex that regulates chromatin 
modification and gene expression (19, 21) (Figure 1C). Other 
essential proteins that make up the core of the MLL1 complex 
include RbBP5, Ash2L, and WDR5 (21). These three proteins 
form a complex that is able to bind a variety of H3K4 methytrans-
ferases with SET domains, including MLL1. Recent biochemical 
and structural analyses of the interactions between the complex 
members reveal that the RbBP5-Ash2L heterodimer interaction 
with MLL1 stabilizes it in the catalytic conformation, whereas 
WDR5 acts as a bridge between the RbBP5-Ash2L complex and 
MLL1 itself (22). The WDR5 bridge is not needed for the interac-
tion between RbBP5-Ash2L and other MLL family members, 
but it is essential for the H3K4 methyltransferase activity of 
MLL1. MLL1 recruits these other components, along with other 
chromatin remodeling proteins such as the histone acetyltrans-
ferases CBP/p300 and hMOF, to specific target genes (21, 23, 24). 
In fact, recruitment of these other histone-modifying proteins, 
particularly hMOF, has recently been shown to be crucial for 
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MLL1 target gene expression, whereas the H3K4 methyltrans-
ferase activity of MLL1 is dispensable in this regard (24).
The N-terminal portion of MLL1 present in translocation-
encoded fusions loses its ability to interact with MLL-C (19). 
The functional consequence of this feature is not clear. In most 
leukemias, residual core complex including MLL-C would be 
expected to be present and retain its histone methyltransferase 
activity, either from expression of the reciprocal fusion (although 
this probably happens only in a minority of patients) or from the 
second, non-rearranged MLL1 allele. There is debate whether 
the second allele is required—on one hand, experimental data 
from knockout mice suggest that it might be (25, 26), on the 
other hand, deletion of the second MLL1 allele has been reported 
in patients (27) and also occurs in the ML2 cell line. Whether 
leukemias with deletions of the MLL1 wild-type allele retain 
residual wild-type function through expression and cleavage of a 
reciprocal fusion is unclear, as is the role of the reciprocal fusion 
in general. Wilkinson et  al. reported that the MLL-AF4 fusion 
activates expression of RUNX1 and that the RUNX1 protein then 
interacts with the AF4-MLL reciprocal fusion and the MLL-C 
complex proteins (28). The authors hypothesized that interaction 
of AF4-MLL enhances its coactivation of RUNX1 target genes, 
although they were not able to successfully target AF4-MLL via 
siRNA for functional confirmation of this theory. Furthermore, 
a reciprocal translocation predicted to result in the expression of 
a reciprocal fusion transcript was found in only 24 of 182 MLL-
rearranged (MLL-r) patients (29). The fact that in most patients 
the reciprocal fusion is likely not expressed strongly argues 
against a critical role.
Physiologic Functions of MLL1
MLL1 is both structurally and functionally homologous to the 
Drosophila melanogaster protein trithorax (1), which is involved 
in epigenetic regulation of defined developmental genes [reviewed 
in Ref. (30)]. Homozygous deletion of Mll1 in murine embryos 
results in lethality at E10.5–E12.5, with null embryos showing 
abnormal facial development and innervation of embryonic 
structures, as well as abnormal fetal hematopoiesis (31–33). 
Mll1 ± (heterozygous) embryos display both body segmentation 
abnormalities and decreased numbers of cells of several hemat-
opoietic lineages. Many of these defects closely resemble those 
seen upon knockout of developmental patterning genes, such as 
the homeobox (Hox) genes, many of which (Hoxa9, Hoxa7, and 
Hoxc8) have been identified as Mll1 target genes. Although Hox 
genes are expressed in Mll1−/− embryos before the E9.0 stage, their 
expression is not maintained at later time points in the absence 
of Mll1 (34). These findings indicate that Mll1 is required for the 
maintenance, and not the initiation, of Hox gene expression. In 
steady-state adult murine hematopoiesis, hematopoiesis-specific 
knockout of Mll1 resulted in moderate to severe impairment of 
stem cell function (35, 36).
Identification of MLL1 target genes involved in embryogenesis 
and hematopoiesis has been the goal of multiple studies. MLL1 
has been reported to occupy as much as 5,000 genes in leukemia 
cell lines and cultured lymphoblasts (37) and a smaller number 
of genes in fibroblasts (38). MLL1 binding correlated with the 
presence of H3K4me3 and occupancy of RNA polymerase 
II, suggesting that despite the presence of multiple negative 
regulatory domains in the MLL1 protein, the net outcome of 
MLL1 binding is typically transcriptional activation. Despite 
correlation of MLL1 binding with H3K4 trimethylation, MLL1 
is not the methyltransferase responsible for the deposition of 
the majority of H3K4 trimethylation in any tissue examined to 
date, as knockout does not result in decreased global levels of 
H3K4me3 (24).
NORMAL FUNCTiONS OF THe COMMON 
MLL1 FUSiON PARTNeRS
Leukemia-associated translocations involving 11q23 have been 
shown to generate in-frame fusions of the MLL1 gene to more 
than 80 different partner genes (29). N-terminally truncated 
MLL1 alone is not sufficient to transform cells (39, 40). This 
finding argues for a crucial contribution on the part of the fusion 
partner proteins to leukemogenesis. Although the proteins 
encoded by the 80 + MLL1 partner genes seemingly have diverse 
structures and functions, two common features have emerged 
that likely have importance for the oncogenic potential of the 
chimeric protein. First, many of the partners, including the 
ones most frequently encountered in MLL1 fusions, are nuclear 
proteins involved in the regulation of transcriptional elongation 
[though interaction with the positive transcription elongation 
factor b (pTEFb) complex and phosphorylation of Pol II] and 
direct or indirect recruitment of the H3K79 histone methyl-
transferase DOT1L (41–49). Second, many partners, including 
those that are cytoplasmic, have been shown to form complexes 
in the nucleus as fusion proteins (50). A revealing study dem-
onstrated that a fusion construct of Mll exons 1–8 and lacZ, the 
gene encoding the non-oncogenic enzyme β-galactosidase, was 
able to cause leukemias in mice, albeit with longer latency and 
lower incidence than the more traditional Mll-Af9 fusion (51). 
Importantly, the formation of a tetramer is essential for the func-
tionality of the enzyme β-galactosidase, and all of the leukemia 
cells demonstrated β-galactosidase activity, suggesting that the 
fusion proteins also oligomerized. Martin et al. confirmed that 
dimerization of MLL1 is transforming through the fusion of 
MLL1 to FKBP12, an inducible dimerizer (52). A final interesting 
consideration is that N-terminal MLL1 is normally destabilized 
by the loss of interaction with MLL-C (19). The MLL1 fusion 
construct loses the domain necessary for MLL-C binding and 
therefore would be expected to be degraded—since it is not, the 
fusion partner may also play a role in enhancing the stability of 
the fusion protein.
The AF4 Protein Family
The AF4 protein (ALL1-fused gene from chromosome 4) 
is fused in-frame to MLL1 as a result of a t(4,11)(q21,q23) 
translocation (2). This fusion is responsible for approximately 
50% of cases of infant acute lymphoblastic leukemia (ALL) 
with MLL1 rearrangement and more than 75% of adult MLL-r 
ALLs (29). AF4 is a member of the ALF (AF4, LAF-4, FMR-
2) family of nuclear proteins (41, 42). Two additional family 
members (LAF-4 and AF5q31) have been identified in MLL1 
fusions from patient samples (53, 54). These proteins share 
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several regions of homology, including a region rich in serine 
residues that has been shown to have transactivation properties 
in reporter assays and which is conserved in fusions with MLL1 
(55, 56). The functions of the known family members remain 
incompletely characterized. However, AF4 knockout mice 
display significant delays in lymphopoiesis (generation of B 
and T cells) (57). AF4 has been shown to interact with pTEFb 
and DOT1L (44–46). pTEFb is a complex of cyclin T1/T2 and 
cyclin-dependent kinase 9 (CDK9), which phosphorylates the 
C-terminal domain of RNA polymerase II and thus promotes 
transcriptional elongation (58). AF4 binding to pTEFb enhances 
PolII-CTD phosphorylation and promotes gene transcription. 
AF4 family members may also interact with another transcrip-
tional complex, selectivity factor 1 (SL1), which is composed 
of TATA-binding protein and four associated factors, and 
this association may play a role in direct recruitment of RNA 
polymerase II to target genes (59).
AF9 and eNL
ALL1-fused gene from chromosome 9 (AF9) and eleven-nineteen 
leukemia (ENL) are the second and third most common fusion 
partners of MLL1, and these fusions arise from the t(9,11)
(p22,q23) and t(11,19)(q23,p13.3) translocations, respectively 
(29). MLL-AF9 is most commonly associated with myeloid 
leukemias, while MLL-ENL is prevalent in both lymphoid and 
myeloid leukemias (60). AF9 and ENL have highly similar 
structures. Both proteins have a conserved C-terminal coiled 
coil region with transactivation properties that is necessary and 
sufficient for leukemic transformation in the context of MLL1 
fusions (40). Furthermore, AF9 and ENL have also been shown 
to interact with AF4 via their C-termini and thus be part of 
AF4 containing complexes that also bind pTEFb and DOT1L 
(44–49). The C-terminal domains mediating this interaction are 
conserved in MLL1 fusions (43) and mutation of the DOT1L-
binding domain of ENL in MLL-ENL cells abrogated colony 
formation and reduced Hox gene expression typically associated 
with transformation (45).
Similar to MLL1, AF9 and ENL have roles in the epigenetic/
transcriptional control of developmental pathways (31, 61). 
Wild-type AF9 in mice and humans seems to have a regulatory 
function specifically in megakaryocyte/erythrocyte lineages 
(61, 62). AF9 and ENL have been shown to interact with the 
protein Polycomb 3, also known as CBX8, a component of 
polycomb repressive complex 1 (PRC1), which is implicated 
in maintenance of stable repression of genes, and with certain 
isoforms of the BCL-6 corepressor (45, 63–65). However, rather 
than mediating transcriptional repression, the role of CBX8 in 
the context of MLL fusions appears to mediate the recruitment 
of the histone acetyl transferase Tip60, thereby promoting 
fusion target gene expression (66). Finally, the N-terminal 
YEATS domain of ENL and AF9 have reader function rec-
ognizing histone proteins 1 and 3 (H1 and H3) acetylation 
and, as recently demonstrated, crotonylation (49, 67–69). The 
wild-type AF9 YEATS domain has been reported to be criti-
cally involved in the recruitment of DOT1L to chromatin and 
H3K79 methylation-mediated transcriptional control [(49) and 
see “DOT1L Inhibitors” section]; however, in the MLL1 fusion, 
the YEATS domain is typically excluded (40). It is possible that 
the N-terminal MLL1 fragment supplies this function; however, 
this has been difficult to experimentally confirm. The precise 
function of these various binding partners to the function of 
AF9 or ENL in their wild-type or MLL1-fused states will still 
require more investigation.
AF10 and AF17
AF10 was the first MLL1 fusion partner to be shown to interact 
with DOT1L (70). AF10 and the structurally related AF17 (also a 
rare fusion partner) are consistently co-purified with DOT1L and 
part of the canonical DOT-complex (47). AF10 is required for di- 
and tri- (although not mono-) methylation of H3K79 by DOT1L 
(71). The PHD finger of AF10 specifically binds to unmodified 
H3K27 (72). Although both AF10/AF17 and AF9/ENL co-purify 
with DOT1L, it is unclear whether all these proteins reside in one 
or in two separate complexes and what the relationship of these 
complexes is to elongation complexes containing AF4, AF5, and 
pTEFb or SL1 (46–48, 59).
TRANSCRiPTiONAL DYSReGULATiON iN 
THe CONTeXT OF MLL1 FUSiONS
Controversies Around and Potential Roles 
of an Oncogenic Multiprotein Complex
The cooperation of most major MLL1 fusion partners in a 
single elongation regulatory complex, termed “super elongation 
complex” (SEC), “AF4/ENL family protein complex,” or “ENL-
associated protein complex”, offered an elegant explanation for 
the large number of different partners: translocation of any of 
the members of a large complex containing AF10, AF17, AF9, 
ENL, ELL, AF4, AF5, pTEFb, and DOT1L would cause aberrant 
transcriptional elongation and similar phenotypes. However, 
such a super complex containing an MLL fusion has remained 
elusive, and careful mapping of binding sites has shown that 
binding of several of these members is mutually exclusive, sug-
gesting several smaller, rather than one large complex [(46–48, 
73, 74); Figure 2].
Furthermore, this theory did not explain the different clinical 
phenotypes observed in dependence of the fusion partner (dis-
cussed below). It also did not provide an explanation for the 
transforming activity of MLL fusions with partners such as 
cytosolic coiled coil domain proteins, CBP, septins, and the MLL 
partial tandem duplication (PTDs). Despite a vast amount of 
mechanistic knowledge, MLL rearrangements thus still defy a 
simple and unifying theory of how they cause leukemia.
The Gene expression Program Controlled 
by MLL1 Fusions
Genome-wide comparisons of gene expression in MLL-r vs MLL 
wild-type leukemias have consistently demonstrated that this 
set of leukemias—irrespective of fusion partner or myeloid vs 
lymphoid differentiation—is distinct from all other leukemia 
subtypes with respect to its gene expression signature (75–77). 
The most frequently overexpressed genes in MLL-r leukemias 
are the later HOX cluster genes (particularly HOXA7-HOXA10) 
FiGURe 2 | Putative complexes between mixed-lineage leukemia (MLL) fusions and nuclear proteins involved in histone modifications and 
transcriptional elongation. MEN1, Menin; FP, fusion partner. AF10, AF17, AF9, ENL, ELL, AF4, and AF5 have all been reported as MLL1 fusion partner, as well as 
interaction partner with each other, DOT1L, and pTEFb. However, DOT1L and pTEFb most likely do not reside within one large complex (73, 74). Red stars depict 
opportunities for targeted inhibition—Protein–protein: (1) Menin-MLL1 interaction. Chromatin: (2) LEDGF—H3K36me2 interaction (blocking reader domain or 
ASH1L). (3) AF10—unmodified H3K27 interaction (blocking reader domain or demethylases?). (4) DOT1L—placement of H3K79me2/3 (blocking methyltransferase 
domain). Pol II phosphorylation: (5) Inhibition of pTEFb. Downstream targets: (6) FLT3.
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and the HOX cofactor MEIS1 (78, 79). HOX genes encode 
transcription factors whose activities control developmental 
processes such as segmentation and hematopoiesis (31, 34, 78, 
80). In these functions, they appear to have somewhat redundant 
roles (80, 81). In the hematopoietic system, both HOX genes 
and MEIS1 are expressed at highest levels in the stem cells and 
early lineage progenitor cells, and expression levels are down-
regulated with differentiation (80, 81). Persistent expression of 
both MEIS1and HOX genes has been observed in a wide variety 
of leukemias (78, 82). Investigations into the dependence of 
MLL-r leukemias on upregulation of these genes have shown 
that MEIS1 is necessary for leukemia growth and proliferation 
and that levels of expression of MEIS1 correlate inversely with 
disease latency (83). The dependence of MLL-r leukemias for 
individual Hox genes appeared somewhat less consistent, likely 
due to functional redundancy among HOX members (81, 84, 
85). However, it seems safe to say that dysregulated expression 
of the HOX developmental regulators and their cofactor MEIS1 
contributes critically to the stem cell-like characteristics of MLL-r 
leukemias and confers or maintains on these cells self-renewal 
properties, growth, and survival advantages that promote their 
oncogenic potential.
These stem cell-like properties—which may also in part 
depend on the developmental stage at which the leukemia arose 
(stem cell vs early progenitor)—have been proposed to contribute 
to the high level of resistance to programmed cell death frequently 
observed in the clinic (86–91). In addition, frequent dysregula-
tion of prosurvival pathways such as BCL-2, which counteracts 
the intrinsic mitochondria-mediated apoptotic pathway, may 
contribute to the therapeutic difficulties many of these leukemias 
pose in the clinical setting (89, 92).
CLiNiCAL FeATUReS OF MLL-r 
LeUKeMiAS
Demographics and Common Features
As the name suggests, MLL rearrangements are found in mixed-
lineage leukemias [now named mixed phenotype acute leukemia 
(MPAL) (93)]. For the most part, however, leukemias arising from 
rearrangements of the MLL gene manifest as either acute lym-
phoid or acute myeloid leukemias (ALL or AML, respectively), 
and only a minority of MPAL actually carry MLL rearrange-
ments. MLL-r leukemias make up approximately 10% of acute 
leukemias in all age groups (94). There is a bimodal distribution 
of affected patients, with MLL rearrangements most commonly 
found in ALL in infants less than 12 months of age and in a much 
broader age range of older children or adults, with AML slightly 
more common than ALL in this age range (94). Finally, there is 
a rare entity known as “therapy-related leukemia,” which typi-
cally occurs after exposure to topoisomerase II inhibitors (e.g., 
etoposide, doxorubicin) (95, 96).
In the case of infant leukemias, the incidence of MLL rear-
rangements is 70–80% (29, 97). Therapy-related leukemias 
secondary to the aforementioned chemotherapeutic agents also 
harbor MLL translocations in at least 70% of cases (98, 99). Of 
all patients treated with topoisomerase II inhibitors, between 
2 and 12% go on to develop secondary leukemias (100). The 
majority of these are AML, although a smaller number of cases 
of ALL have also been reported (96). The latency period for this 
group of leukemias, in contrast to leukemias secondary to other 
types of carcinogens, is extremely short—as early as 6  months 
postexposure, and generally within 24–48 months of exposure, 
to topo-II inhibitors (95, 96, 98, 100). The mechanisms behind 
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the development of MLL-r leukemias will be explored in the 
“Environmental and Genetic Risks” section.
MLL-r as a subgroup of acute leukemias is associated with 
certain phenotypic features that set it apart from other classes 
of leukemias. MLL-r acute leukemias, particularly in infants, 
are more likely to present with hyperleukocytosis and CNS 
involvement (101–103). In cases of MLL-r B-ALL, the blasts are 
typically of the pro-B phenotype and lack expression of CD10/
common acute lymphoblastic leukemia antigen and frequently 
show coexpression of myeloid markers (104). This is also true in 
many cases of MLL-r leukemias in adults (105). In vitro, MLL-r 
blasts often have resistance to commonly used chemotherapeu-
tic drugs such as prednisone and l-asparaginase, but typically 
have acute sensitivity to cytarabine (106). It has been reported 
that the transporter protein that imports Ara-C across the cell 
membrane, the human equilibrative nucleoside transporter 1, 
was expressed at 2.5-fold higher levels in a cohort of leukemia 
cells with MLL rearrangements than in MLL wild-type leu-
kemias (107). It is possible that enhanced transport of Ara-C 
across cell membranes leads to preferential accumulation of 
the drug in MLL-r cells, which contributes to their specific 
sensitivity.
Common MLL Fusion Partners and 
Lineage Plasticity
The majority of MLL-r leukemias involve fusions of MLL with 
one of six common partner genes: AF4 [t(4,11)], AF9 [t(9,11)], 
ENL [t(11,19)(q23,p13.3)], AF10 [t(10,11)], ELL [t(11,19)
(q23,p13.1)], or AF6 [t(6,11)] (29). The relative frequency of 
these fusions with respect to leukemia subtype and age are 
shown in Figure 3 [data adapted from the study by Meyer et al. 
(29)]. Translocations may or may not be observable on karyo-
type analysis, but are more reliably identified by fluorescence 
in situ hybridization (101, 104).
Clinical evidence suggests that the fusion partner of MLL1 
is a major determinant of the ultimate leukemia phenotype. In 
patients, MLL-AF4 is predominantly associated with lymphoid 
malignancies, whereas MLL-AF9 more often results in myeloid 
malignancies (29). At the same time, particularly, the lymphoid 
MLL-r leukemias retain a substantial amount of lineage infidel-
ity and lineage plasticity. This is evident in the frequent co-
expression of myeloid markers and is the phenomenon familiar 
to every clinician of MLL-r B-ALL patients who relapse with 
apparent AML that is cytogenetically related or even identical 
to the initial lymphoid disease. This phenomenon is likely to 
increase, as therapies directed against B-lymphoid cell surface 
markers enter expanded clinical use (antibodies, antibody–drug 
conjugates, bispecific antibodies such as blinatumomab, and 
CAR-T). Relapse with leukemia that has adopted a myeloid fate 
was recently reported for two of seven patients treated with a 
CD19 directed CAR-T (108) and in an infant with t(4,11) ALL 
treated with blinatumomab (109). This plasticity is also reflected 
the recurrent finding of MLL rearrangements in leukemias of 
ambiguous lineage (MPAL) (93, 110). Experimentally, Wei et al. 
demonstrated that the microenvironment can play a role in lineage 
determination. On transduction of human HSCs with a retroviral 
MLL-AF9 construct, transformed cells propagated in culture 
with cytokines that promote myeloid differentiation invariably 
expressed myeloid surface markers (111). Despite the association 
of MLL-AF9 with myeloid features, transformed cells exposed 
to cytokines that promote lymphoid differentiation expressed 
both B cell and myeloid markers. Importantly, leukemia cells 
of different phenotype from lymphoid or myeloid culture were 
found to be clonally related, suggesting that they arose from a 
single leukemia stem cell. Therefore, although the fusion partner 
affects the leukemia phenotype, environmental cues and selective 
pressure can also contribute.
In addition to translocations, in-frame PTD of exons 5-12 
or a portion thereof can be seen in acute leukemias (112, 113). 
This type of MLL mutation was originally described in adult de 
novo AML patients with normal karyotype and has since been 
demonstrated in both childhood and adult ALL and AML as well 
as in therapy-related leukemia (112), with an overall incidence 
of 5–10% (113). MLL-PTD has also been found in a number of 
leukemias with extra copies of chromosome 11 (114). The pres-
ence of this abnormality is associated with early relapse of disease 
following initial remission (113, 114).
environmental and Genetic Risks
When translocated, disruption of the MLL gene typically occurs 
within the breakpoint cluster region (BCR), which spans an 8.3-
kb region from exon 8 to exon 14, inclusive (115, 116). A number 
of sites within this portion of MLL are vulnerable to damage. 
Among them are the scaffold attachment regions (SARs), which 
are areas of contact between DNA and non-histone proteins of 
the chromatin scaffold. Two such SARs have been identified 
within the MLL coding region—one 5’ to the BCR and a stronger 
one within the 3’ part of the BCR (117). Cleavage sites of topoi-
somerase II are also found scattered throughout the MLL BCR, 
with a higher density in the SAR that overlaps the 3’ region of 
the BCR. Topoisomerase II is an enzyme that is essential for the 
relaxation of supercoiled DNA during chromatin remodeling 
processes (100, 116). Drugs that inhibit the enzyme, such as 
epipodophyllotoxins and certain alkylating agents, typically do so 
by forming a stable ternary complex with the enzyme and DNA. 
The resulting double-strand breaks are most likely to be repaired 
by non-homologous end joining.
Topoisomerase II inhibitors such as etoposide are known 
to be associated with development of MLLs in therapy-related 
cases, and the breakpoints within the MLL gene are frequently 
adjacent to known cleavage sites of the enzyme (116, 118). 
Potential MLL cleavage by unknown apoptosis-activated 
proteases that seem to act independently of topoisomerase II 
has also been reported in response to stimuli such as ionizing 
radiation (119). Interestingly, the majority of MLL breakpoints 
identified in infant leukemias lie toward the 3’ end of the BCR, 
similar to those seen in leukemias secondary to treatment with 
topoisomerase II inhibitors (115–117). This finding suggests a 
possible common mechanism for these two groups of leukemias. 
Along those lines, investigations into prenatal exposures of 
infants with MLL-r leukemia have suggested that bioflavonoids 
found in foods and herbal remedies such as dipyrone (“Mexican 
aspirin”); senna in herbal teas; quercetin, a bioflavonoid found 
in onions, red wine, and other foods; and genistein found in 
FiGURe 3 | Mixed-lineage leukemia (MLL)-rearranged leukemias involve fusions of 11q23 with 1 of more than 80 different partner genes. Six or seven 
fusion partners are responsible for the majority of cases. The pie chart illustrates the relative frequencies of the different fusion partners in acute lymphoblastic 
leukemia (ALL) and acute myeloid leukemias (AML), respectively. Numbers are adapted from the published data by Meyer et al. (29). The bottom half of the figure 
shows the breakdown of the relative frequencies of MLL fusion partners based on the leukemia type (ALL vs AML) and age group.
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soybean products could act as inhibitors of topoisomerase II 
(100, 120, 121) and promote rearrangement of the MLL locus 
in a variety of cells, including CD34+ hematopoietic progeni-
tor cells (120, 122). Therefore, it seems possible that, at least in 
some instances, in utero exposure to environmentally occurring 
topoisomerase II poisons could contribute to the develop-
ment of MLL-rearrangements. However, most of these agents 
are very common, and infant leukemia is a very rare disease. 
This discrepancy has not well resolved and suggests additional 
stochastic or genetic mechanisms.
It is also important to note that, in very young patients, there 
is substantial evidence that the gene rearrangement usually, if 
not always, occurs in  utero. Polymerase chain reaction (PCR) 
testing of neonatal blood spots has demonstrated the presence 
of translocations involving the MLL gene even in babies whose 
disease was diagnosed months later (123). Twin studies offer 
further support for the prenatal origin of these leukemias. The 
concordance rate for infant leukemia in identical twins is pre-
dicted to be close to 100%, and siblings typically have identical 
MLL breakpoints (123, 124). These observations suggest a trans-
placental transfer of leukemia cells from one twin to the other. 
Despite a rate of twin–twin transfusions of 8% in dichorionic 
twins, the rate of transplacental seeding of leukemia is much 
lower in this situation. Both immune-mediated and genetic 
mechanisms may be responsible for this discrepancy. In fact, 
there is emerging evidence that genetic risk factors contribute 
to MLL-r leukemogenesis. In a remarkable GWAS study, a rare 
polymorphism in MLL3 was present in 100% of infants with 
MLL-r leukemia (125). The mechanistic implications of this 
variant are currently being explored.
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TReATMeNTS AND OUTCOMeS FOR 
MLL-r LeUKeMiAS
Principles and Outcomes of Multiagent 
Chemotherapy
Historically, the 5-year event-free survival (EFS) for infant ALL 
has ranged from 20 to 40% for those with MLL rearrangements, 
vs 60% or higher for those with wild-type MLL (102, 104). The 
most recent studies for whom published long-term survival data 
exist have indicated only modest improvement in these numbers 
[4-year EFS of 40–50% and overall survival (OS) of 50–55%] 
(102, 126, 127). Most patients (~80–90%) will go into remission 
initially, but relapse rates of 50–60% are reported, the most com-
mon site of relapse being the bone marrow (128). Intensification 
of chemotherapy may reduce the risks of relapse, but comes at the 
cost of significant therapy-related morbidity and mortality, mostly 
of infectious etiology (104). In contrast, the cases of MLL-r AML 
in infants do not generally have worse outcomes than their non-
MLL-r AML counterparts (129). Pediatric patients greater than 1 
year of age with MLL-r ALL are better than infants, although not 
as well as their non-MLL-r counterparts. Most recent data esti-
mate a 5-year EFS of ~60% (129) compared to ~92% in pediatric 
ALL overall (130). In a European study of 85 adult ALL patients 
with t(4,11) rearrangements (105), 5-year EFS and OS were 34 
and 35%, respectively, which is slightly diminished compared to 
~40–45% long-term survival in adult ALL overall (131). Again, 
most MLL-r patients achieve an initial remission (>90%), but 
many patients ultimately relapse.
The relationship between MLL rearrangements and outcome 
in AML is less straightforward than in ALL. The most com-
mon MLL fusion in AML, MLL-AF9, has been reported to be 
associated with an intermediate to good prognosis (132, 133). 
In contrast when analyzing a large cohort of pediatric de novo 
AML with a variety of different MLL rearrangements, 5-year 
EFS and OS were poorer [44% EFS and 56% OS (133)] when 
compared to pediatric AML in general [55% EFS and 70% OS 
(134)], with substantial differences depending on the fusion 
partner.
Clinical features that have been shown to be predictive of 
outcome in infant MLL-r ALL include age at diagnosis, total white 
blood cell count at diagnosis, presence or absence of CD10 on 
blast cells, and initial response to steroid therapy (97, 104, 126, 
128, 129). Age cutoff predictive of poorest outcomes varies based 
on the study (<90 days vs <6 months). WBC count >300K, lack 
of CD10 expression, and poor response to prednisone (defined 
as >1,000 blast cells per microliter in the peripheral blood) all 
confer particularly dismal outcomes as well (97, 104, 126, 128, 
129). In adult MLL-r ALL, older age (>25  years) was the only 
independent factor associated with decreased survival [<35 vs 
71% (105)].
Historically, it was thought that t(4,11) fusions in ALL were 
associated with poorer survival compared to other translocations 
(128). However, despite the association of t(4,11) and t(11,19) 
fusions with younger age groups, more recent trials have failed 
to find any significant association between relapse or survival in 
MLL-r ALL and any particular fusion partner (97, 104, 126, 129). 
This may be related to the fact that despite a myriad of fusion 
partners being reported, only a few dominate the clinical experi-
ence. Furthermore, MLL-r leukemias are typically not treated 
on a unified protocol, but managed largely based on phenotype 
(AML vs ALL) and age (infant leukemia). Most current clinical 
risk stratifications do not take the fusion partner into account. 
However, several studies investigating the relationship between 
fusion partner and outcome have suggested that there is a correla-
tion. A meta-analysis of the association between fusion partner 
and outcome in 756 children with MLL-r AML from 11 study 
groups operating in 15 countries suggested massively divergent 
OS: while 24 children with the t(1,11)(q21,q23) translocation 
(MLL-AF1q) had an OS of 100% (event free survival, EFS 92%), 
EFS and OS were 11 and 22%, respectively, for patients with the 
t(6,11)(q27,q23) translocation (MLL-AF6) (133). This study 
did not confirm the possible “good risk” feature of the common 
MLL-AF9 translocation that was previously reported (132). The 
dismal outcome for MLL-AF6 mutant disease had previously 
been reported in adults (135). Also, children older than 1 year 
with MLL-AF4 (and interestingly, MLL-AF9) mutant B-ALL were 
reported to have a worse outcome than children with other MLL 
translocation partners (129). In an even more fascinating twist, 
MLL-AF9 might be predictive of a good OS when it occurs in FAB 
M5-AML as opposed to other FAB subgroup AML or ALL PIMD 
(133). Whether this reflects statistical outliers in an increasingly 
smaller and more finely sliced “pie,” genetic/pharmacogenomics 
differences, or underlying biology (possibly reflecting cell of 
origin) is unclear.
One interesting correlation is that both infant ALL and 
 therapy-related leukemias, which have overall the worst outcomes 
of MLL-r leukemias, are associated with breakpoints in intron 
11 rather than intron 9 or 10 (115). Emerenciano et al. recently 
demonstrated that the presence of MLL breakpoint in intron 11 
was also an independent predictor of poor survival in a cohort 
of 30 MLL-r pediatric leukemia patients (136). Fragmentation 
of the MLL gene at intron 11 is predicted to generate an MLL 
C-terminal truncated protein whose PHD fingers are misfolded, 
eliminating the ability to associate with its repressive complex 
(137). The authors of this study theorize that, in these cases, 
unbalanced activation functions of the resultant MLL fusion 
protein lead to more aggressive leukemia phenotypes. Whether 
this can be mechanistically proven in future experiments remains 
to be seen.
The Role of Hematopoietic Stem Cell 
Transplant (HSCT) in the Treatment of 
MLL-r Leukemia
The role of HSCT in the treatment of MLL-r leukemias continues 
to be a matter of intense debate, with several studies and meta-
analyses suggesting that HSCT does not improve survival in 
MLL-r leukemias at any age group or lineage, with the excep-
tion of therapy-associated AML (126, 129, 133, 138–141). The 
combined analysis of the North American CCG 1953 and POG 
9407 infant ALL trials concluded that HSCT failed to show any 
benefit  (142). Initial chemotherapy was identical on the two 
protocols. In the later phases, chemotherapy was very similar, 
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with the main difference being methotrexate dosing. Patients on 
the CCG also received maintenance therapy, while patients on 
the POG trial did not. On the CCG trial, HSCT in CR1 was the 
preferred mode of treatment if a suitable donor could be identi-
fied, whereas on the POG trial, this was left to the judgment of 
the investigator. The recommended conditioning consisted of 
Ara-C/Cy/TBI, although only about half of the patients received 
this conditioning. Transplant-related mortality, particularly in 
children receiving TBI, was high. This study included 132 infants 
with MLL rearrangement, although after adjustment for time to 
transplant, only 100 children were evaluable. Fifty-three under-
went HSCT, 47 did not. Five-year EFS for children who were 
alive at the time of transplant was similar between the HSCT and 
chemotherapy groups (48.85 vs 48.7%), prompting the authors 
to conclude that HSCT did not improve survival in MLL-r infant 
ALL. In addition, there were no differences in subgroups based 
on WBC, age, or CD10 expression. However, the comparatively 
smaller number of patients with high-risk features and variability 
in transplant regimen made the subgroup analysis for this patient 
population difficult.
No benefit for HSCT for infants with MLL-r leukemia was 
also shown by two retrospective analyses (129, 143) and in a 
report of children treated in Europe (144). In contrast, the analy-
sis of a larger cohort of 297 infants with MLL rearrangement 
treated on Interfant99 identified a group of patients less than 
6  months of age with either a WBC of >300,000, prednisone 
poor response, or high end consolidation MRD that had an 
extremely poor survival with chemotherapy only (97, 145, 146). 
On Interfant99, high-risk patients did benefit from HSCT: the 
survival for children <6 months with either a WBC > 300,00 or 
PPR who were alive at the time of HSCT was only 22.2% when 
treated with chemotherapy and 59% on the HSCT arm (97). The 
number of patients who received HSCT was small, but given the 
dismal outcome of this subgroup, a more aggressive approach 
seems justified. The outcome of a similar group of infants on 
other trials such as CCG 1953 and POG 9407 is not known, 
since the number of patients was smaller, prednisone response 
and MRD were not assessed or reported, and WBC criteria for 
subgroup analysis were different from the Interfant99 study 
(97, 104).
In summary, although numbers are small, HSCT is likely 
beneficial for a defined subgroup of high-risk infants, particu-
larly if conditioning regimen and donor choice allow for a low 
transplant-related mortality. There are no data supporting HSCT 
in CR1 in older children with MLL-r ALL or de novo AML. As 
discussed earlier, the study by Balgobind et  al. suggests that 
defined fusion partners may be associated with a particularly 
poor prognosis (133); however, currently, this is not used for 
treatment stratification in either ALL or AML. In contrast to de 
novo leukemia, outcomes for therapy-related AML are substan-
tially worse, and HSCT in first CR is standard of care (141). In 
addition to tAML, treatment-related MLL-r ALL is occasionally 
seen. Although outcomes for tAML are inferior to de novo 
AML, no such data exist for MLL-r tALL vs de novo ALL, and 
chemotherapy only may be the treatment of choice, particularly 
for patients who show a good response to therapy (as measured 
by MRD).
Role of FLT-3 in MLL-r Leukemias
One of the most significantly upregulated genes in the tran-
scriptional profile of MLL-r leukemias is Fms-like receptor 
tyrosine kinase-3 (FLT-3) (75). This gene encodes a class III 
receptor tyrosine kinase, which is closely related to KIT, FMS, 
and platelet-derived growth factor receptor (147). Under 
physiologic conditions, binding of the FLT-3 ligand leads to 
dimerization and phosphorylation of the receptor, which acti-
vates downstream signaling pathways such as PI3K/Akt, Ras/
MAPK, and Stat5 (147). Activating mutations in FLT-3 have 
been described in a variety of hematologic malignancies, but 
have primarily been characterized in pediatric and adult AML 
(147, 148). The two types of activating mutations commonly seen 
in these contexts are internal tandem duplications in the jux-
tamembrane domain of FLT-3 [so-called FLT-3 internal tandem 
duplications (ITD) mutations] and point mutations within the 
tyrosine kinase domain (TKD) that confer constitutive activity to 
the enzyme (147). The presence of a FLT-3 ITD mutation confers 
an extremely poor prognosis (148).
FLT-3 gene upregulation in MLL-r leukemias correlates 
to overexpression of the FLT-3 protein in these ALL samples 
compared to non-MLL-r leukemias, which has been demon-
strated by several groups (149–152). On average, MLL-r infant 
ALL (which is the most thoroughly studied subtype of MLL-r 
leukemias) expresses 37-fold higher FLT-3 protein compared to 
normal bone marrow and 2- and 16-fold higher expression of 
FLT-3 compared to non-MLL-r ALL in children less than 1 year 
of age and older children, respectively (150, 152). By contrast, 
the data have been less consistent with respect to activating 
mutations of FLT-3, with most of the recent studies suggesting 
that they are rare (149–151, 153). FLT-3 ITD have not been 
demonstrated in recent cohorts of MLL-r ALL patients, and 
FLT-3 TKD mutations have an approximate incidence of only 
3–18% in MLL-r ALL (149–151). Most recently, Andersson 
et al. investigated a cohort of 85 infant and pediatric patients 
with ALL, of which 67 had MLL rearrangements. Of these, only 
four patients had FLT-3 mutations, two of which were TKD 
mutations and two of which were present only in a minor clone 
(154). This finding is also consistent with the general finding 
by this group that MLL-r leukemias, in particular those aris-
ing in infants, have one of the lowest frequencies of somatic 
non-silent mutations of any other type of cancer (mean 1.3 per 
major clone). Nevertheless, in vitro studies have demonstrated 
that high levels of FLT-3 expression, even in the absence of these 
activating mutations, are associated with phosphorylation and 
activation of the protein (149, 150).
Mouse models of MLL-r leukemias have suggested cooperation 
between the MLL fusion oncoprotein and FLT-3 in the progres-
sion to the leukemia phenotype (155). In addition, a retrospective 
study showed correlation of high levels of FLT-3 expression with 
poor outcomes in 32 MLLr infants treated on Interfant99 (36 vs 
71% 1-year EFS in high vs low FLT-3 expressing leukemias) (156). 
A later study by Chillon et al. confirmed these findings—of 17 
patients with MLL-AF4 B-ALL, none of those with high FLT-3 
expression were alive at 1 year, compared to 71% of patients with 
low FLT-3 expression (152). FLT-3 expression levels were not 
predictive of outcomes in patients with non-MLL-r ALL. These 
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findings suggested that targeting of FLT-3 in MLL-r patients 
might be a beneficial therapeutic approach.
In vitro cytotoxicity experiments with MLL-r ALL patient 
samples demonstrated in  vitro sensitivity to the FLT-3 kinase 
inhibitors, with response correlating with the amount of FLT-3 
overexpression [PKC412 (150) and CEP-701/lestaurtinib (151)). 
Furthermore, synergy studies between CEP-701 and standard 
chemotherapeutic agents (e.g., etoposide, daunomycin) suggested 
that timing is critical—administration of CEP-701 after cytotoxic 
agents yielded synergistic cytotoxicity, whereas administration of 
CEP-701 before cytotoxic chemotherapy was antagonistic (157). 
These studies laid the groundwork for the design of clinical trials 
to test the efficacy of FLT-3 inhibitors.
Several clinical trials involving FLT-3 inhibitors have been 
conducted in both adult and pediatric leukemias. Of primary 
relevance to MLL-r leukemias is the Therapeutic Advances in 
Childhood Leukemia & Lymphoma (TACL) study, whose results 
have just been published (158). This study was a phase 1 trial 
evaluating the safety of quizartinib (AC220) in combination with 
high-intensity chemotherapy for relapsed childhood leukemia. 
Quizartinib is a second-generation kinase inhibitor designed to 
be potently active against FLT-3 and is more selective than first-
generation inhibitors such as lestaurtinib (159, 160). Twenty-two 
patients were enrolled, of which 18 had relapsed AML (9 with 
FLT-3 mutations) and 4 had relapsed MLL-r ALL (3 infants and 
1 teenager). Patients received combination chemotherapy with 
cytarabine and etoposide (days 1–5) followed by quizartinib 
(days 7–28) for 1–2 cycles. In all cases, target-specific activity of 
quizartinib was demonstrated with near-maximal (>95%) sup-
pression of FLT-3 phosphorylation in plasma inhibitory assays 
(PIAs). Dose-limiting toxicities attributable to the targeted 
agent involved primarily GI toxicities such as elevated lipase or 
transaminases or nausea/vomiting/diarrhea. Of the 17 evaluable 
patients for response, better response correlated with the presence 
of FLT-3 ITD mutations in the AML patients. Three of the four 
MLL-r ALL patients could be evaluated for disease response—one 
had stable disease and two had progressive disease. The study was 
not powered to make conclusions about statistically significant 
impacts on OS.
Another trial specific to infant leukemia, the Children’s 
Oncology Group (COG) trial AALL0631, has been recently 
closed, and data analysis is ongoing. This trial was a rand-
omized, phase III trial of the FLT-3 inhibitor lestaurtinib in 
combination with intensive cytotoxic chemotherapy for newly 
diagnosed infants with MLL-r ALL. Although the final results 
of the trial have not yet been published, the results from the 
TACL trial raise concern that FLT3 inhibition may not be the 
breakthrough that is so desperately needed for these patients. 
However, final results on the outcomes and the depth of FLT-3 
inhibition achieved in AALL0631 regimen is not (yet) known, 
thus failure to achieve sufficient target inhibition remains a pos-
sible explanation for the lack of efficacy. It is also critical to keep 
in mind that in both AALL0631 and the TACL study, the assays 
used to determine the degree of FLT3 inhibition measures the 
inhibitory effect of patient serum on BAF3 cells that are Flt3 
dependent (PIA). The threshold at which this very sensitive 
indicator cell line responds may be different from responses 
in patients’ leukemia cells. It may be necessary to determine 
on-target activity in actual patient cells and correlate that with 
response to get a better sense for whether FLT3 inhibition is of 
therapeutic value in MLL-r leukemia.
Proteasome inhibitors
Proteasome inhibitors are increasingly being integrated into 
therapeutic regimens for a variety of malignancies. The rationale 
behind their use has traditionally been that cancer cells, due to 
increased cell turnover, are more dependent on the proteasome 
machinery for protein recycling than are normal cells. These drugs 
have yielded mixed results when used alone or in combination 
with cytotoxic chemotherapy for a variety of malignancies and 
are associated with significant toxicities, particularly neurotoxic-
ity [reviewed in Ref. (161)].
Accumulating data now suggest that proteasome inhibitors 
may be promising agents to supplement the treatment of MLL-r 
leukemias. Liu et al. noted that the expression levels of MLL fusion 
proteins was not excessive in leukemic cells and hypothesized that 
tight regulation of fusion protein expression might be achieved 
through the proteasome machinery. Indeed, they demonstrated 
that proteasome inhibitor treatment increased the protein levels 
of both wild-type MLL and, to a greater extent, MLL fusion 
proteins (162). Stabilization of MLL fusions activated transcrip-
tion of CDKN1B, which encodes p27, via PAX5. Of note, PAX5 
is selectively expressed in pro-B cells (163). Consistent with this 
model, proteasome inhibitor treatment was associated with a 
dose-dependent decrease in cell viability in lymphoid, but not 
myeloid, MLL-r leukemia cell lines. A cohort of five adult patients 
with MLL-r leukemias were then treated compassionately with 
single agent bortezomib. Three patients (two with pro-B pheno-
type and one with biphenotypic leukemia) had transient hema-
tologic responses to the drug, one for over a year. Two patients 
with myeloid phenotype had no response to proteasome inhibitor 
therapy.
Bortezomib was also identified through high-throughput 
drug screens as an active agent against models of infant MLL-r 
leukemias (164, 165). Mechanistically, Koss et  al. found that 
bortezomib treatment led to decreased histone 2B ubiquitina-
tion (H2Bub). H2Bub is required for the methylation of H3K79 
mono- to di- and trimethylation (166), and knockdown of the 
H2B ubiquitin ligase RNF20 led to decrease in H3K79me2 mark 
at MLL target gene sites and in vitro and in vivo compromise of 
leukemia cell viability (167). Both the study by Liu et al. (162) 
and Wang et al. (167) also explored the effect of bortezomib in 
NF-kB signaling. Intact NF-kB has been reported to be required 
for MLL-fusion-mediated leukemogenesis in a murine model 
(168, 169), and bortezomib has been implicated in negatively 
regulating NF-kB via the accumulation of IkBa in the absence 
of proteasomal degradation (170). However, both Liu et al. (162) 
and Koss et al. (164) found no evidence of NF-kB modulation, 
suggesting that this pathway is not mechanistically involved in 
therapeutic effect. Taken together, proteasome inhibitors may 
be useful as adjunctive therapy for MLL-r leukemias, and bort-
ezomib in combination with standard chemotherapy and HDAC 
inhibition is currently being evaluated in clinical trials for MLL-r 
ALL (NCT02419755, see next section).
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HDAC inhibitors
Similar to proteasome inhibitors, HDAC inhibitors (HDACi) 
have been reported by multiple groups to be active in MLL-r 
leukemias, with effects being attributed to diverging mechanisms 
(165, 171–174). HDACs are a large family of proteins named 
for the ability of the founding member, HDAC1, to deacetylate 
histones. However, many members of the family are cytosolic 
proteins named HDAC due to structural homology, but without 
possessing histone deacetylase function. Several HDACs have 
been reported to be overexpressed in pediatric ALL; however, 
there is no agreement as to which members are specifically 
deregulated (175–177).
The earliest functional relevance of HDACs was suggested by 
a study investigating the activity of valproic acid in MLL-r leuke-
mia. Valproic acid induced growth inhibition and cell-cycle arrest 
in MLL-r leukemia cell lines and primary samples. The authors 
proposed upregulation of p21 as a mechanism (171). Stumpel 
et al. showed that romidepsin (FK288) and vorinostat had activity 
in 2 t(4,11) B-ALL cell lines and 15 infant B-ALL patient samples 
(172). Good, although not as profound, sensitivity to HDAC 
inhibition was also found for non-MLL rearranged B-ALL. They 
also demonstrated decrease in expression of MLL-AF4 at both 
the transcript and protein levels, raising the possibility that effect 
of these drugs is primarily due to downregulation of the MLL 
fusion itself.
In contrast, Stubbs et  al. found that several HDACis were 
broadly active against a variety of different cytogenetic subtypes 
of B-ALL, including (but not exclusively) MLL-r leukemias 
(174). Genetic knockdown as well as class-specific inhibitors 
suggested that HDAC1 and 2 are the critical HDACs in B-ALL, 
with knockdown or inhibition resulting in direct cytotoxicity 
and DNA damage. DNA damage as a result of HDAC inhibition 
has been suggested to underlie the frequently observed synergy 
with chemotherapy. Stubbs et  al. proposed that the particular 
sensitivity of B-ALL to HDAC inhibition could also relate to the 
role of HDAC1 and HDAC2 in early B-cell development (178). 
On the other hand, two studies suggested that inhibition of 
HDAC3 is critically responsible for the activity of HDACis in 
B-ALL (179, 180).
Bhatla et al. published sensitivity of the t(4,11) B-ALL cell line 
RS4,11 to the HDACi vorinostat, and vorinostat was shown to 
be synergistic with standard chemotherapeutic agents such as 
prednisolone and cytarabine (173). The authors of this study also 
specifically investigated relapsed B-ALL (irrespective of karyo-
type) and proposed the reversal of the “relapse gene signature” 
as a mechanism. Finally, an interesting mechanism was proposed 
by Ahmad et al., who proposed that HDACis reactivate wild-type 
MLL to counteract the transcriptional functions of MLL-AF4 or 
other fusions (181). However, the role of wild-type MLL in MLL-r 
leukemia is controversial as discussed above, and the experiments 
by Ahmad et  al. were performed in HeLa cells, with unclear 
implications for the context of leukemia.
From a clinical standpoint, a 2011 case study reported a 
sustained complete cytogenetic response to single-agent panobi-
nostat in an elderly man with therapy-related MLL-r leukemia 
(182). St. Jude Children’s Research Hospital has an ongoing phase 
II clinical trial combining a proteasome inhibitor (bortezomib) 
and an HDACi (vorinostat) in combination with cytotoxic 
chemotherapy for pediatric patients with relapsed or refractory 
MLL-r leukemias (NCT02419755). Chemotherapy backbone 
varies depending on the leukemia phenotype (ALL vs AML), 
and all drugs are intended as a bridge to transplant. A report of 
six “pilot” patients with relapsed/refractory MLL-r leukemia was 
presented at the 2014 American Society of Hematology Annual 
Meeting. The overall response rate of this cohort to chemotherapy 
in combination with bortezomib and vorinostat was 83%: four 
patients had complete response, one patient had partial response, 
and one patient had stable disease (164). Whether this regimen 
can achieve durable responses without excess toxicity in these 
patients remains an ongoing question, but initial results are 
certainly promising.
Hypomethylating Agents
Two separate groups have investigated the methylation status of 
MLL-r leukemias compared to MLL-wild-type leukemias and 
normal controls (183, 184). Global promoter hypermethylation 
was seen in the MLL-r leukemias relative to both non-MLL-r 
leukemias and normal samples, leading to downregulation or 
silencing of a subset of tumor suppressor genes. Retrospective 
analysis demonstrated a statistically significant correlation 
between degree of methylation and risk of relapse (183). 
Furthermore, hypomethylating agents zebularine and decitabine 
showed preferential cytotoxicity to MLL-r cells compared to other 
leukemic cells. Both decitabine and another hypomethylating 
agent, 5-azacitidine, are FDA approved for treatment of myelo-
dysplastic syndromes and AML in adult patients, particularly 
those with co-morbidities limiting other therapeutic options 
[reviewed in Ref. (185)]. 5-azacitidine, but not decitabine, usage 
was associated with increased OS in these patients. These data 
form the basis for a clinical trial run by the National Cancer 
Institute (NCT02828358), and for a new COG therapy trial 
(AALL15P1), both for infant MLL-r ALL, which test the toler-
ability of 5-azacitidine in combination with standard cytotoxic 
chemotherapy.
Similarly to decitabine and 5-azacitidine, other nucleoside ana-
logs may also target the methylation status of MLL-r leukemias. 
Clofarabine, an powerful cytotoxic adenosine analog, is thought 
to also block DNA methylation through depletion of S-adenosyl 
methionine, which donates methyl groups to DNA methyltrans-
ferase enzymes (186), as has been demonstrated for the related 
molecule cladribine (187). In a recent study by Stumpel et al., low 
doses of clofarabine were cytotoxic to MLL-r leukemias in vitro, 
and clofarabine was synergistically active with cytarabine against 
these cells (188). A variety of clinical trials, none specific to MLL-r 
leukemias, currently incorporate clofarabine into study therapy.
immunotherapy
One of the most exciting new therapeutic approaches in B-ALL 
has been the development of immunotherapies, particularly the 
use of bispecific antibodies (blinatumomab) and engineered 
T-cells (CAR-T) in B-ALL. Most clinical trials using CAR-T 
cells in B-ALL to date have allowed children >1 year and adults 
with MLL rearrangements, but have excluded infants, mostly 
due to difficulties around efficient collection and expansion of 
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autologous T-cells. Infants were included in the early clinical trials 
with blinatumomab (189), and despite theoretical concerns about 
the immaturity of T-cell responses very early in life, some encour-
aging responses were seen [Lia Gore, personal communication 
(109)]. However, MLL-r B-ALL may have “built-in” mechanisms 
to evade immune recognition and/or destruction through their 
lineage plasticity. As mentioned earlier, relapse with leukemia 
that has adopted a myeloid fate has been observed in two out of 
seven patients treated with a CD19-directed CAR-T (108) and in 
an infant with t(4;11) ALL treated with blinatumomab (109). It is 
not yet clear whether this will remain a rare occurrence or emerge 
into a common mechanism of relapse and resistance.
MLL SPeCiFiC PATHwAYS AND 
TARGeTeD iNHiBiTORS iN eARLY 
CLiNiCAL TRiALS
Role of RAS Pathway Mutations  
in MLL-r Leukemias
Mutations in RAS pathway members have been frequently 
described in MLL-r leukemias and are perhaps more prevalent 
than mutations in FLT-3. Prelle et  al. evaluated the incidence 
of secondary mutations in a cohort of 144 pediatric and adult 
patients with MLL-r leukemias, of which 100 individuals had 
t(4;11) mutations and the remaining 44 patients had a variety 
of other fusions. NRAS or KRAS mutations were present in 16 
patients (11.1%) (153). In an independent cohort of 109 infant 
ALL patients screened for NRAS, KRAS, or BRAF, 15 patients 
(13.8%) had mutations in either NRAS or KRAS (190). This group 
also reported a significant decrease in OS was specifically seen 
in patients with RAS mutations in the t(4;11) cohort, but not in 
the overall study group. Additional studies have cited frequency 
of RAS pathway mutations in MLL-r leukemia patients ranging 
from 22 to 45% (191–194).
Recently genome-wide analysis of infant MLL-r and MLL-
wild-type ALLs, in addition to pediatric MLL-r ALL in older 
age groups, was performed as a part of the Pediatric Cancer 
Genome Project (154). This study confirmed that although MLL-
r leukemias in general carry a paucity of additional mutations, 
the most commonly seen mutations involve the RAS pathway. 
However, the variant allele frequencies (VAF) for these mutations 
in the majority of the infant cases were <30%, indicating that 
the individual mutations were present in minor clones within 
the leukemia population. This was also noted for the NRAS 
and KRAS mutations described in the study by Driessen et  al. 
(190). Furthermore, of five RAS pathway-mutated patients with 
matched diagnosis and relapse samples, the mutations were lost 
in two cases and the VAF decreased in one case, suggesting a 
gradual depletion of the RAS-mutated subclone (154). Again, this 
mirrors previous studies by Prelle et al. and Emerenciano et al., 
both of whom documented loss of RAS mutations in two of three 
and in five of 18 relapse samples evaluated, respectively (153, 
192). Furthermore, Emerenciano et al. documented the presence 
of RAS mutations in DNA samples from newborn blood spots for 
two patients in their cohort, one with higher allele frequency than 
at diagnosis of leukemia. This finding suggests the possibility that 
RAS pathway mutations provide a proliferative advantage dur-
ing onset of leukemogenesis, but are not necessary for leukemia 
maintenance in the context of MLL rearrangements.
With the advent of multiple inhibitors of the RAS pathway 
that are either FDA approved or in clinical trials, the question 
whether RAS pathway activation plays a role in MLL-r leukemia 
receives new urgency. It is also possible, similar to FLT3, that 
activation of the pathway can occur in the absence of mutations. 
Kampen et  al., using peptide arrays of normal bone marrow 
and leukemia cells, demonstrated increased phosphorylation of 
MAPK pathway proteins in MLL-r AML samples compared to 
either normal bone marrow or non-MLL-r AML’s (195). MEK 
inhibitors have shown selective activity against MLL-r leukemia 
cell lines and primary samples in vitro in several studies, although 
in almost every case those cells with RAS mutations were more 
sensitive to these drugs than were cells without RAS mutations 
(193–195). The possible exception to this rule lies in leukemia 
cells harboring t(6;11), leading to an MLL-AF6 fusion. Manara 
et al. have shown that the normally cytoplasmic protein AF6 is 
instead localized to the nucleus in the presence of MLL-AF6, 
which is associated with increased RAS pathway activity. The 
AF6 protein has RAS-association domains, and genetic silenc-
ing of MLL-AF6 leads to decreased RAS activity and decreased 
phosphorylation of ERK (196). Furthermore, chemical inhibition 
of RAS signaling by either PD98059 (MEK inhibitor) or tipifarnib 
(farnesyltransferase inhibitor) was selectively toxic to t(6;11) 
leukemia cells. Therefore, although RAS inhibition may not be of 
benefit in the majority of MLL-r leukemias, where mutations are 
subclonal and not likely to impact the survival of the leukemia, 
it may be of benefit in the context of leukemias with MLL-AF6 
fusions, which are notorious for their particularly poor outcomes.
Dot1L inhibitors
The histone 3 lysine 79 methyltransferase Dot1L has been shown 
to be necessary for MLL fusion-mediated transformation in a 
variety of experimental models (45, 70, 197–200), and increased 
levels of H3K79 dimethylation have been demonstrated at MLL 
fusion target gene loci [(70, 198, 201); see also Figure 2]. DOT1L 
contributes to the maintenance of the MLL leukemic gene expres-
sion program at least in part by antagonizing Sirtuin-1-mediated 
repressive epigenetic modifications to H3K9 (202).
A small molecule inhibitor of Dot1L (EPZ-5676 or pinometo-
stat) has been developed by Epizyme, Inc. and is being studied in 
early clinical trials in both adult and pediatric patients with MLL-
r leukemias (NCT01684150 and NCT02141828). Preclinical 
studies demonstrated target specificity and downregulation of 
MLL target genes upon treatment of MLL-r cell lines with EPZ-
5676 (203). EPZ-5676 also demonstrated synergy with other 
chemotherapeutic agents known to target MLL-r leukemias, 
regardless of the order of administration (204). Continuous 
intravenous infusion of the compound caused tumor regression 
and prolonged survival in mice and rat xenograft models of MLL-
r leukemias (203). Unfortunately, the lack of oral bioavailability 
and short half-life of the drug currently mandate the continuous 
IV infusion, resulting in efforts to develop alternative Dot1L 
inhibitors, which maintain specificity and efficacy but are easier 
to administer (205). Data from the phase I/II clinical trials are 
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forthcoming, but it will be crucial to correlate mechanistic effect 
(i.e., reduction of H3K79 methylation) with outcomes in these 
patients. Preliminary data published in abstract form suggest sus-
tained single-agent efficacy in two patients, but also a substantial 
number of patients with only transient or no response, and who 
did not achieve profound depletion of H3K79 methylation at 
MLL-fusion target loci at the dose used (206, 207).
Bromodomain inhibitors
The bromodomain and extra terminal (BET) family of proteins, 
which includes BRD2, BRD3, and BRD4, are a family of chro-
matin adaptor proteins that recognize and bind to acetyl-lysine 
residues. A global proteomic screen identified interaction of these 
proteins with components of the SEC, many of whom are MLL 
fusion partners (208, 209). Simultaneously, an shRNA screen 
identified the BET protein BRD4 as a therapeutic target in MLL-
AF9,NrasG12D murine AML model (210). Inhibitors of BRD4 had 
efficacy in MLL-AF9,NrasG12D model and on a variety of leukemia 
cell lines, with MLL-r leukemias preferentially affected (209, 210). 
Efficacy of BRD4 inhibition was confirmed in primary MLL-r 
patient samples in vitro (165, 209).
In addition to the bromodomain of BET family proteins, the 
bromodomain of CBP/p300 bromodomain has emerged as a 
potential therapeutic target for leukemia, including MLL-r leuke-
mia. A small molecule inhibitor of the CBP/p300 bromodomain 
led to decreased colony formation and promoted differentiation 
in MLL-CBP and MLL-AF9 leukemia models as well as primary 
MLL-r patient cells (211). This latter inhibitor was found to have 
synergistic inhibition of MLL-r cells when combined with the 
bromodomain inhibitor JQ1 or doxorubicin.
One recent study suggested a sequential recruitment of 
DOT1L and BRD4 to a subset of genes located adjacent to super 
enhancers (212). Dimethylation of H3K79 by DOT1L allowed 
binding of histone acetyltransferases including EP500 and 
CREBBP to these regions, which leads to acetylation of H4K5 
and subsequent binding of BRD4 and the SEC. Accordingly, 
inhibition of DOT1L led to dramatically decreased binding of 
BRD4 to chromatin, and the combination of a bromodomain 
inhibitor and a DOT1L inhibitor was synergistically active 
against MLL-r leukemias both in vitro and in vivo. In contrast, 
regulation of distinct programs by DOT1L and BRD4 were 
reported by Garcia-Cuellar et al. (213). DOT1L-dependent loci 
were characterized by promoter-centered binding of MLL-ENL, 
while BRD4-dependent loci exhibited fusion binding beyond 
the termination site. Despite the discrepancies in proposed 
molecular mechanisms, the combination of DOT1L and BRD4 
inhibition may be promising to explore further.
Lysine-Specific Demethylase-1 (LSD1) 
inhibitors
Lysine-specific demethylase-1, also known as KDM1A, has 
been shown to be important for maintenance of MLL target 
gene expression (214) and was identified in an RNAi screen as 
a gene whose repression inhibited growth of MLL-AF9,NrasG12D 
murine cells (215). It has enzymatic specificity for lysines 4 and 
9 on histone 3. Pharmacologic inhibition of LSD1 with tranyl-
cypromine (TCP) was shown to result in a decreased expression 
of MLL target genes; it also impaired colony-forming potential 
and leukemic engraftment in immunodeficient mice (214). 
However, there were significant toxicities to the mice from TCP 
and related inhibitors, particularly related to thrombocytopenia 
and anemia. Using newer generation small-molecule inhibitors of 
LSD1, these results were confirmed in vitro and in vivo without 
any significant toxicities to mice (216). Furthermore, in  vitro 
synergy was demonstrated when LSD1 inhibitors were combined 
with the DOT1L inhibitor SYC-522. However, Shi et  al. were 
only able to demonstrate a detrimental effect of LSD1 inhibition 
in  vitro, whereas no disadvantage of LSD1 inhibition could be 
shown in competitive engraftment experiments in mice (215). 
Pharmacologic inhibitors of LSD1 are in early clinical trials in 
adult AML/MDS (GSK GSK2879552 single agent, NCT02177812, 
Tranylcypromine + ATRA, NCT02717884, NCT02261779, and 
NCT02273102). It remains to be seen whether LSD1 inhibitors 
will have efficacy in patients with MLL-r leukemias.
Polycomb Protein inhibitors
Polycomb repressive complexes 1 and 2 are two protein com-
plexes involved in chromatin modulation and transcriptional 
repression. Both have been implicated in MLL-r leukemias. 
PRC1 contains core components BMI1, RING2A, and RING2B 
and mediates H2Ak119 monoubiquitination. Several groups 
have investigated the functional requirement of these PRC1 
components in MLLr leukemia. Initial reports investigating the 
role of BMI1 using BMI1 knockdown and/or MLL-AF9 leuke-
mias generated on a Bmi1−/− background suggested that PRC1 
canonical function is not required for MLLr leukemogenesis, 
although some transcriptional and minor functional effects on 
leukemia initiating cell frequency were observed (66, 217, 218). 
In contrast, combined knockout of Ring1a/b in a murine model 
of MLL-AF9-induced leukemia was not tolerated (219). The stark 
discrepancy in phenotypic consequences between knockout of 
different PRC1 components have not been well resolved and may 
relate to differently composed subcomplexes and/or functions 
outside of canonical PCR1.
In addition, the non-canonical PRC1 member CBX8 has been 
implicated leukemogenesis particularly mediated by MLL-AF9 
and MLL-ENL. As mentioned earlier, AF9 and ENL bind CBX8 
(63, 64), and leukemia initiation and maintenance in murine 
models MLL-AF9 and MLL-ENL AML were dependent on CBX8 
(66). CBX function in MLLr leukemia appears to be independent 
of its role in PRC1, however, and instead involve the recruitment 
of the histone acetyl transferase Tip60 to fusion target loci (66). 
This is further supported by the finding that binding of CBX8 
to ENL reverses the repressor activity of CBX8 (220). In mouse 
models, deletion of CBX8 had no detrimental effect on normal 
hematopoiesis, suggesting CBX8 and/or Tip60 could be interest-
ing target for future development of inhibitors.
PRC2 consists of the canonical components EZH2, EED, and 
SUZ12. EZH2 is a histone methyltransferase targeting H3K27. 
Multiple groups have documented decreased proliferation, 
differentiation, and loss of stem cell potential in MLL fusion 
leukemias when any component of the complex was geneti-
cally knocked down or deleted (215, 221–223). This effect was 
most prominent with depletion of the universal components of 
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the complex, EED or SUZ12, whereas EZH1 and EZH2 have 
somewhat redundant functions (215, 221). Impairment of the 
leukemia phenotype was largely attributable to de-repression of 
INK4A and ARF, although deregulation of other PRC2 target 
genes such as GATA2 and EGR1 were also implicated (223). 
Two inhibitors (DZNep and UNC1999) have shown efficacy 
in vitro against MLL-r leukemias and have prolonged survival 
in xenograft models of disease (224, 225). Another small mol-
ecule inhibitor, which disrupts the protein–protein interaction 
between EZH2 and EED, has had similar utility in MLL-AF9 
models without any effect on non-transformed cells (222). 
However, inactivating mutations in PRC2 components has also 
been observed in AML and MDS patients and at least in MDS 
correlates with poor prognosis. As an added wrinkle to the story, 
the observation that AF10, a necessary cofactor for H3K79 di- 
and trimethylation by DOT1L, binds unmodified H3K27 (72) 
suggests that inhibition of EZH2 or PRC2 components could 
also facilitate H3K79 methylation on MLL-fusion target genes, 
although there is currently no experimental data to document 
that this is the case. Pharmacologic inhibitors of EZH2 are in 
clinical trials for diseases where PRC2/EZH2 hyperfunction is 
clearly linked to malignant transformation (such as lymphomas 
with activating EZH2 mutations or INI1-negative solid tumors). 
EZH2 inhibition is not currently investigated in clinical trials for 
AML or MLL-r leukemias.
Agents that Counteract Antiapoptotic 
Mechanisms
As previously mentioned, MLL-r leukemias have been reported 
to be resistant to programmed cell death (86–89). Leukemias 
with t(4,11) translocations (MLL-AF4) tend to have elevated lev-
els of prosurvival BCL-2 protein, which counteracts the intrinsic 
mitochondria-mediated apoptotic pathway (89). In vitro cyto-
toxicity studies of the pan-BCL-2 family inhibitor obatoclax 
demonstrated efficacy of this agent against a panel of MLL-r 
infant leukemias as well as MLL-r cell lines (165, 226); obatoclax 
also synergized with multiple standard chemotherapeutic agents 
(226). Recent work has suggested that t(4,11) leukemias tend to 
have highest expression of BCL-2 of multiple classes of acute 
leukemias and that the MLL-AF4 protein upregulates BCL-2 
expression via DOT1L-mediated H3K79 methylation (92). 
The selective BCL-2 inhibitor, ABT199 (venetoclax), which has 
shown promise in clinical trials against chronic lymphocytic 
leukemia and other hematopoietic malignancies (227–229), was 
effective both in vitro and in xenograft models against MLL-r 
leukemias in combination with cytotoxic chemotherapies and 
with a DOT1L inhibitor. Further work in xenograft models 
confirms not only the enhanced sensitivity of MLL-r leukemias 
to BCL-2 inhibition compared to other subgroups of ALL but 
also the enhanced efficacy of combined inhibition of BCL-2 and 
BCL-XL (230). These data suggest yet another class of targeted 
agents that may prove useful adjuncts to therapy in MLL-r 
leukemias.
Cell Cycle Checkpoint inhibitors
Recent studies have identified cyclin-dependent kinase 6 
(CDK6) as a target gene of MLL fusion proteins (231). CDK6 
binds to D cyclins and promotes cell cycle progression through 
phosphorylation and inhibition of target genes such as RB1. 
MLL-r leukemias seem to be dependent on CDK6, but not on 
CDK4, for growth and proliferation (231, 232). This dependence 
on CDK6 was not seen in non-MLL-r leukemias. Furthermore, 
treatment of either MLL-r cell lines or primary patient AML cells 
with the CDK6 inhibitor palbociclib (PD0332991) led to both 
growth inhibition, decreased colony formation, and a differenti-
ated phenotype (232). Third-generation transplant recipient 
mice given palbociclib-treated MLL-AF9 cells had decreased 
disease burden and prolonged survival compared to mice given 
MLL-AF9 control cells. These preclinical data suggest that CDK6 
is a potential target for MLL-r leukemias; accordingly, there is 
an active phase Ib/IIa clinical trial out of the University of Ulm 
(NCT02310243) of palbociclib as monotherapy for adults with 
MLL-r leukemias.
Menin inhibitors
As mentioned earlier, the protein Menin interacts with the 
N-terminal portion of the MLL1 protein and has been shown to be 
essential for MLL fusion protein leukemogenesis [(6–9); see also 
Figure 2]. Menin also interacts with wild-type MLL1, and studies 
in mice have shown that genetic deletion of Menin affects long-
term hematopoietic stem cell potential and B-lineage lymphoid 
progenitors (233). The therapeutic window of Menin inhibition 
for MLL-r leukemias is therefore uncertain. Nonetheless, several 
groups have developed small molecule inhibitors that disrupt the 
interaction between MLL1 and Menin and have shown in vitro 
and in  vivo impairment of leukemia growth and proliferation, 
irrespective of the MLL fusion partner (234–237). As these 
studies were all short-term experiments with murine models of 
MLL-r leukemias, longer-term preclinical models will be essen-
tial studies to perform before development of clinical trials with 
these agents.
Dinaciclib
Due to the association of common MLL fusion partners in the 
SEC with pTEFb, the role of specific pTEFb inhibitors has also 
been examined as potentially useful in targeting MLL-r leukemias 
(Figure 2). The efficacy of the CDK9 inhibitor (part of the pTEFb 
complex) Flavopiridol on MLL-r leukemia cells has long been 
recognized (46). Dinaciclib, which inhibits the CDK9 component 
of pTEFb, showed efficacy in preclinical models both in vitro and 
in vivo, inducing apoptotic cell death in MLL-r leukemia models 
and inhibition of MLL target genes (165, 238). No toxicity data 
were reported in these studies, so it remains to be seen whether 
this inhibitor will demonstrate appropriate specificity for MLL 
target genes without causing inordinate toxicity due to global 
repression of RNA polymerase II.
FiNAL THOUGHTS
MLL translocations lead to aberrant expression of stem cell 
genetic programs in hematopoietic cells, which leads to a par-
ticularly aggressive subtype of leukemias in children and adults. 
Outcomes with conventional chemotherapy remain suboptimal 
to dismal, and hematopoietic stem cell transplantation has 
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not proven to be beneficial except in the most high-risk infant 
patients. Despite extensive resources and manpower devoted to 
a better understanding of MLL fusion biology, we still possess an 
inadequate understanding of the pathophysiology of this disease. 
Accompanying the ever increasing number of fusion partners 
identified is the ever widening circle of epigenetic regulators 
thought to be involved in genetic dysregulation upon expression 
of MLL translocations. However, in the era of targeted therapies, 
we may finally be at the cusp of discovering combinations of 
therapeutic agents that can improve the outcomes for these 
patients.
AUTHOR CONTRiBUTiONS
Both authors conducted extensive literature review and co-wrote 
the final manuscript.
ACKNOwLeDGMeNTS
This work was supported by NIH/NCI R01CA201230 (salary 
support to KB), 5T32CA082086-16 (salary support to AW), and 
funds from the Children’s Hospital of Colorado (salary support 
to KB and AW).
ReFeReNCeS
1. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila 
trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 
(1992) 71:691–700. doi:10.1016/0092-8674(92)90602-9 
2. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, et  al. The 
t(4,11) chromosome translocation of human acute leukemias fuses the ALL-1 
gene, related to Drosophila trithorax, to the AF-4 gene. Cell (1992) 71:701–8. 
doi:10.1016/0092-8674(92)90603-A 
3. Butler LH, Slany R, Cui X, Cleary ML, Mason DY. The HRX proto-oncogene 
product is widely expressed in human tissues and localizes to nuclear struc-
tures. Blood (1997) 89(9):3361–70. 
4. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee 
JC, et al. Menin associates with a trithorax family histone methyltransferase 
complex and with the Hoxc8 locus. Mol Cell (2004) 13:587–97. doi:10.1016/
S1097-2765(04)00081-4 
5. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, et al. 
Menin and MLL cooperatively regulate expression of cyclin-dependent 
kinase inhibitors. Proc Natl Acad Sci U S A (2005) 102(3):749–54. doi:10.1073/
pnas.0408836102 
6. Yokoyama A, Somervaille TCP, Smith KS, Rozenblatt-Rosen O, Meyerson 
M, Cleary ML. The Menin tumor suppressor protein is an essential onco-
genic cofactor for MLL-associated leukemogenesis. Cell (2005) 123:207–18. 
doi:10.1016/j.cell.2005.09.025 
7. Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, et al. The tumor 
suppressor Menin regulates hematopoiesis and myeloid transformation 
by influencing Hox gene expression. Proc Natl Acad Sci U S A (2006) 
103:1018–23. doi:10.1073/pnas.0510347103 
8. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of 
MLL amino terminal sequences with Menin is required for transformation. 
Cancer Res (2007) 67(15):7275–83. doi:10.1158/0008-5472.CAN-06-2369 
9. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF 
on cancer-associated target genes. Cancer Cell (2008) 14:36–46. doi:10.1016/j.
ccr.2008.05.003 
10. Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, et al. ASH1L links histone 
H2 lysine 36 dimethylation to MLL leukemia. Cancer Discov (2016) 7:770–83. 
doi:10.1158/2159-8290.CD-16-0058 
11. Ma Q, Alder H, Nelson KK, Chatterjee D, Gu Y, Nakamura T, et al. Analysis 
of the murine All-1 gene reveals conserved domains with human ALL-1 and 
identifies a motif shared with DNA methyltransferases. Proc Natl Acad Sci U 
S A (1993) 90:6350–4. doi:10.1073/pnas.90.13.6350 
12. Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the 
“AT-hook” cruciform DNA-binding region and the transcriptional repres-
sion domain from the activation domain of the mixed-lineage leukemia 
(MLL) gene. Proc Natl Acad Sci U S A (1994) 91:10610–4. doi:10.1073/
pnas.91.22.10610 
13. Yano T, Nakamura T, Blechman J, Sorio C, Dang CV, Geiger B, et al. Nuclear 
punctate distribution of ALL-1 is conferred by distinct elements at the 
N-terminus of the protein. Proc Natl Acad Sci U S A (1997) 94:7286–91. 
doi:10.1073/pnas.94.14.7286 
14. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA meth-
yltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 
(2000) 24:88–91. doi:10.1038/71750 
15. Birke M, Schreiner S, Garcia-Cuellar MP, Mahr K, Titgemeyer F, Slany RK. 
The MT domain of the proto-oncoprotein MLL binds to CpG-containing 
DNA and discriminates against methylation. Nucleic Acids Res (2002) 
30:958–65. doi:10.1093/nar/30.4.958 
16. Tschiersch B, Hofmann A, Krauss V, Dorn R, Korge G, Reuter G. The protein 
encoded by the Drosophila position-effect variegation suppressor gene 
Su(var)3-9 combines domains of antagonistic regulators of homeotic gene 
complexes. EMBO J (1994) 13:3822–31. 
17. Chen J, Santillan DA, Koonce M, Wei W, Luo R, Thirman JM, et al. Loss of 
MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem 
cell immortalization. Cancer Res (2008) 68(15):6199–207. doi:10.1158/0008-
5472.CAN-07-6514 
18. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis D, et al. MLL 
targets SET methyltransferase activity to Hox gene promoters. Mol Cell 
(2002) 10:1107–17. doi:10.1016/S1097-2765(02)00741-4 
19. Hsieh JJD, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer 
SJ. Proteolytic cleavage of MLL generates a complex of N- and C-terminal 
fragments that confers protein stability and subnuclear localization. Mol Cell 
Biol (2003) 23(1):186–94. doi:10.1128/MCB.23.1.186-194.2003 
20. Hsieh JJD, Cheng EHY, Korsmeyer SJ. Taspase-1: a threonine aspartase 
required for cleavage of MLL and proper HOX gene expression. Cell (2003) 
115:293–303. doi:10.1016/S0092-8674(03)00816-X 
21. Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, et al. Regulation 
of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct 
Mol Biol (2006) 13(8):713–9. doi:10.1038/nsmb1128 
22. Li Y, Han J, Zhang Y, Cao F, Liu Z, Li S, et al. Structural basis for activity 
regulation of MLL family methyltransferases. Nature (2016) 530:447–52. 
doi:10.1038/nature16952 
23. Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ. MLL and CREB 
bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell 
Biol (2001) 21:2249–58. doi:10.1128/MCB.21.7.2249-2258.2001 
24. Mishra BP, Zaffuto KM, Artinger EL, Org T, Mikkola HKA, Cheng C, et al. 
The histone methyltransferase activity of MLL1 is dispensable for hema-
topoiesis and leukemogenesis. Cell Rep (2014) 7:1239–47. doi:10.1016/j.
celrep.2014.04.015 
25. Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, et  al. MLL-AF9-
induced leukemogenesis requires coexpression of the wild-type Mll allele. 
Cancer Cell (2010) 17:148–59. doi:10.1016/j.ccr.2009.12.034 
26. Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, et al. Multiple 
interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus 
in leukeomgenesis. Mol Cell (2010) 38:853–63. doi:10.1016/j.molcel.2010. 
05.011 
27. Lim JH, Jang S, Park CJ, Chi HS, Lee JO, Seo EJ. FISH analysis of MLL gene 
rearrangements: detection of the concurrent loss or gain of the 3’ signal and 
its prognostic significance. Int J Lab Hematol (2014) 36:571–9. doi:10.1111/
ijlh.12192 
28. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 
is a key target in t(4,11) leukemias that contributes to gene activation through 
an AF4-MLL complex interaction. Cell Rep (2013) 3:116–27. doi:10.1016/j.
celrep.2012.12.016 
29. Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, 
et al. The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 
27:2165–76. doi:10.1038/leu.2013.135 
16
Winters and Bernt MLL—An Update
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 4
30. Schuettengruber B, Martinez AM, Iovino N, Cavalli G. Trithorax group 
proteins: switching genes on and keeping them active. Nat Rev Mol Cell 
Biol (2011) 12:799–814. doi:10.1038/nrm3230 
31. Yu BD, Hess JL, Horning SE, Brown GAJ, Korsmeyer SJ. Altered Hox 
expression and segmental identity in Mll-mutant mice. Nature (1995) 
378(6556):505–8. doi:10.1038/378505a0 
32. Yagi H, Deguchi K, Aono A, Tani Y, Kishimoto T, Komori T. Growth 
disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood (1998) 
92:108–17. 
33. Yokoyama A, Ficara F, Murphy MJ, Meisel C, Naresh A, Kitabayashi I, 
et  al. Proteolytically cleaved MLL subunits are susceptible to distinct 
degradation pathways. J Cell Sci (2011) 124:2208–19. doi:10.1242/jcs. 
080523 
34. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian 
trithorax-group gene, functions as a transcriptional maintenance factor in 
morphogenesis. Proc Natl Acad Sci U S A (1998) 95:10632–6. doi:10.1073/
pnas.95.18.10632 
35. McMahon KA, Hiew SYL, Hadjur S, Veiga-Fernandes H, Menzel U, Price 
AJ, et  al. Mll has a critical role in fetal and adult hematopoietic stem cell 
self-renewal. Cell Stem Cell (2007) 1:338–45. doi:10.1016/j.stem.2007. 
07.002 
36. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and inde-
pendent roles for MLL in adult hematopoietic stem cells and progenitors. 
Cell Stem Cell (2007) 1:324–37. doi:10.1016/j.stem.2007.05.019 
37. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani 
E, et  al. Global and Hox-specific roles for the MLL1 methyltransferase. 
Proc Natl Acad Sci U S A (2005) 102(24):8603–8. doi:10.1073/pnas. 
0503072102 
38. Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL 
associates specifically with a subset of transcriptionally active target genes. 
Proc Natl Acad Sci U S A (2005) 102(41):14765–70. doi:10.1073/pnas. 
0503630102 
39. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, et  al. An 
Mll-AF9 fusion gene made by homologous recombination causes acute 
leukemia in chimeric mice: a method to create fusion oncogenes. Cell (1996) 
85:853–61. doi:10.1016/S0092-8674(00)81269-6 
40. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL 
requires the transcriptional transactivation activity of ENL and the DNA 
binding motifs of HRX. Mol Cell Biol (1998) 18(1):122–9. doi:10.1128/
MCB.18.1.122 
41. Ma C, Staudt LM. LAF-4 encodes a lymphoid nuclear protein with trans-
activation potential that is homologous to AF-4, the gene fused to MLL in 
t(4,11) leukemias. Blood (1996) 87:734–45. 
42. Li Q, Frestedt JL, Kersey JH. AF4 encodes a ubiquitous protein that in both 
native and MLL-AF4 fusion types localizes to subnuclear compartments. 
Blood (1998) 92:3841–7. 
43. Erfurth F, Hemenway CS, de Erkenez AC, Domer PH. MLL fusion partners 
AF4 and AF9 interact at subnuclear foci. Leukemia (2004) 18:92–102. 
doi:10.1038/sj.leu.2403200 
44. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner 
AF4 stimulates RNA polymerase II transcriptional elongation and mediates 
coordinated chromatin remodeling. Hum Mol Genet (2007) 16(1):92–106. 
doi:10.1093/hmg/ddl444 
45. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, 
et al. A role for the MLL fusion partner ENL in transcriptional elongation 
and chromatin modification. Blood (2007) 110(13):4445–54. doi:10.1182/
blood-2007-05-090514 
46. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK. 
Misguided transcriptional elongation causes mixed lineage leukemia. PLoS 
Biol (2009) 7(11):1–14. doi:10.1371/journal.pbio.1000249 
47. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, et al. Linking 
H3K79 trimethylation to Wnt signaling through a novel Dot1-containing 
complex (DotCom). Genes Dev (2010) 24:574–89. doi:10.1101/gad. 
1898410 
48. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order 
complex containing AF4 and ENL family proteins with P-TEFb facilitates 
oncogenic and physiologic MLL-dependent transcription. Cancer Cell 
(2010) 17(2):198–212. doi:10.1016/j.ccr.2009.12.040 
49. Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, et al. AF9 YEATS domain 
links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 
(2014) 159:558–71. doi:10.1016/j.cell.2014.09.049 
50. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes 
to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 
(2003) 4:99–110. doi:10.1016/S1535-6108(03)00188-0 
51. Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH. Tumorigenesis 
in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ 
gene. EMBO J (2000) 19(5):843–51. doi:10.1093/emboj/19.5.843 
52. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, et  al. 
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. 
Cancer Cell (2003) 4:197–207. doi:10.1016/S1535-6108(03)00214-9 
53. Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y. AF5q31, 
a newly identified AF4-related gene, is fused to MLL in infant acute 
lymphoblastic leukemia with ins(5,11)(q31,q13q23). Proc Natl Acad Sci U 
S A (1999) 96:14535–40. doi:10.1073/pnas.96.25.14535 
54. von Bergh AR, Beverloo HB, Rombout P, van Wering ER, van Weel MH, 
Beverstock GC, et al. LAF4, an AF4-related gene, is fused to MLL in infant 
acute lymphoblastic leukemia. Genes Chromosomes Cancer (2002) 35:92–6. 
doi:10.1002/gcc.10091 
55. Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, et al. Domains 
with transcriptional regulatory activity within the ALL1 and AF4 proteins 
involved in acute leukemia. Proc Natl Acad Sci U S A (1995) 92:12160–4. 
doi:10.1073/pnas.92.26.12160 
56. Bitoun E, Davies KE. The robotic mouse: unraveling the function 
of AF4 in the cerebellum. Cerebellum (2005) 4:250–60. doi:10.1080/ 
14734220500325897 
57. Isnard P, Core N, Naquet P, Djabali M. Altered lymphoid development in 
mice deficient for the mAF4 proto-oncogene. Blood (2000) 96(2):705–10. 
58. Peterlin BM, Price DH. Controlling the elongation phase of transcription 
with P-TEFb. Mol Cell (2006) 23:297–305. doi:10.1016/j.molcel.2006. 
06.014 
59. Okuda H, Kanai A, Ito S, Matsui H, Yokoyama A. AF4 uses the SL1 com-
ponents of RNAP1 machinery to initiate MLL fusion- and AEP-dependent 
transcription. Nat Commun (2015) 6:8869. doi:10.1038/ncomms9869 
60. Drynan LF, Pannell R, Forster A, Chan NMM, Cano F, Daser A, et  al. 
Mll fusions generated by Cre-loxP-mediated de novo translocations can 
induce lineage reassignment in tumorigenesis. EMBO J (2005) 24:3136–46. 
doi:10.1038/sj.emboj.7600760 
61. Collins EC, Appert A, Ariza-McNaughton L, Pannell R, Yamada Y, Rabbitts 
TH. Mouse Af9 is a controller of embryo patterning, like Mll, whose human 
homologue fuses with AF9 after chromosomal translocation in leukemia. 
Mol Cell Biol (2002) 22(20):7313–24. doi:10.1128/MCB.22.20.7313- 
7324.2002 
62. Pina C, May G, Soneji S, Hong D, Enver T. MLLT3 regulates early human 
erythroid and megakaryocytic cell fate. Cell Stem Cell (2008) 2:264–73. 
doi:10.1016/j.stem.2008.01.013 
63. Garcia-Cuellar MP, Zilles O, Schreiner SA, Birke M, Winkler TH, Slany 
RK. The ENL moiety of the childhood leukemia-associated MLL-ENL 
oncoprotein recruits human Polycomb 3. Oncogene (2001) 20:411–9. 
doi:10.1038/sj.onc.1204108 
64. Hemenway CS, de Erkenez AC, Gould GCD. The polycomb protein MPc3 
interacts with AF9, and MLL fusion partner in t(9,11)(p22,q23) acute 
leukemias. Oncogene (2001) 20:3798–805. doi:10.1038/sj.onc.1204478 
65. Srinivasan RS, de Erkenez AC, Hemenway CS. The mixed lineage leukemia 
fusion partner AF9 binds specific isoforms of the BCL-6 corepressor. 
Oncogene (2003) 22:3395–406. doi:10.1038/sj.onc.1206361 
66. Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, et  al. 
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leu-
kemogenesis. Cancer Cell (2011) 20:563–75. doi:10.1016/j.ccr.2011.09.008 
67. Zeisig DT, Bittner CB, Zeisig BB, Garcia-Cuellar MP, Hess JL, Slany RK. 
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion 
partners with chromatin. Oncogene (2005) 24:5525–32. doi:10.1038/sj.onc. 
1208699 
68. Li Y, Sabari BR, Panchenko T, Wen H, Zhao D, Guan H, et al. Molecular 
coupling of histone crotonylation and active transcription by AF9 
YEATS domain. Mol Cell (2016) 62:181–93. doi:10.1016/j.molcel.2016. 
03.028 
17
Winters and Bernt MLL—An Update
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 4
69. Andrews FH, Shanle EK, Strahl BD, Kutateladze TG. The essential 
role of acetyllysine binding by the YEATS domain in transcriptional 
regulation. Transcription (2016) 7:14–20. doi:10.1080/21541264.2015. 
1125987 
70. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links his-
tone methylation to leukemogenesis. Cell (2005) 121:167–78. doi:10.1016/j.
cell.2005.02.020 
71. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, et al. 
AF10 regulates progressive H3K79 methylation and HOX gene expression 
in diverse AML subtypes. Cancer Cell (2014) 26:896–908. doi:10.1016/j.
ccell.2014.10.009 
72. Chen S, Yang Z, Wilkinson AW, Desphande AJ, Sidoli S, Krajewski K, 
et  al. The PZP domain of AF10 senses unmodified H3K27 to regulate 
DOT1L mediated methylation of H3K79. Mol Cell (2015) 60(2):319–27. 
doi:10.1016/j.molcel.2015.08.019 
73. Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KSJ, Allis CD, 
et  al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion 
proteins through distinct partner protein complexes. Proc Natl Acad Sci U 
S A (2011) 108(38):15751–6. doi:10.1073/pnas.1111498108 
74. He N, Chan CK, Sobhian B, Chou S, Xue Y, Liu M, et  al. Human poly-
merase-associated factor complex (PAFc) connects the super elongation 
complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U 
S A (2011) 108(36):E636–45. doi:10.1073/pnas.1107107108 
75. Armstrong SA, Staunton JE, Silverman LB, Pieters R, Den Boer ML, Minden 
MD, et al. MLL translocations specify a distinct gene expression profile that 
distinguishes a unique leukemia. Nat Genet (2002) 30:41–7. doi:10.1038/
ng765 
76. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. 
Classification, subtype discovery, and prediction of outcome in pediatric 
acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 
(2002) 1:133–43. doi:10.1016/S1535-6108(02)00032-6 
77. Rozovskaia T, Ravid-Amir O, Tillib S, Getz G, Feinstein E, Agrawal H, et al. 
Expression profiles of acute lymphoblastic and myeloblastic leukemias with 
ALL-1 rearrangements. Proc Natl Acad Sci U S A (2003) 100(13):7853–8. 
doi:10.1073/pnas.1132115100 
78. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. 
Hoxa9 transforms primary bone marrow cells through specific collaboration 
with Meis1a but not Pbx1b. EMBO J (1998) 17:3714–25. doi:10.1093/
emboj/17.13.3714 
79. Li Z, Luo RT, Mi S, Sun M, Chen P, Bao J, et al. Consistent deregulation of 
gene expression between human and murine MLL rearrangement leukemias. 
Cancer Res (2009) 69:1109–16. doi:10.1158/0008-5472.CAN-08-3381 
80. Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK, 
et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 
have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 
(1997) 89:1922–30. 
81. So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic trans-
formation of hematopoietic progenitors by MLL-GAS7 in the absence 
of Hoxa7 or Hoxa9. Blood (2004) 103:3192–9. doi:10.1182/blood-2003- 
10-3722 
82. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression 
of HOX genes, HOX cofactors, and MLL in phenotypically and functionally 
defined subpopulations of leukemic and normal human hematopoietic cells. 
Leukemia (1999) 13:687–98. doi:10.1038/sj.leu.2401410 
83. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential 
and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 
(2007) 21:2762–74. doi:10.1101/gad.1602107 
84. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-
Eibrink M, et al. HOXA9 is required for survival in human MLL-rearranged 
acute leukemias. Blood (2009) 113:2375–85. doi:10.1182/blood-2007-09- 
113597 
85. Kumar AR, Li Q, Hudson WA, Chen W, Sam T, Yao Q, et  al. A role for 
MEIS1 in MLL-fusion gene leukemia. Blood (2009) 113:1756–8. doi:10.1182/
blood-2008-06-163287 
86. Kersey JH, Wang D, Oberto M. Resistance of t(4,11) (MLL-AF4 fusion gene) 
leukemias to stress-induced cell death: possible mechanism for extensive 
extramedullary accumulation of cells and poor prognosis. Leukemia (1998) 
12:1561–4. doi:10.1038/sj.leu.2401148 
87. Inukai T, Zhang X, Goto M, Hirose K, Uno K, Akahane K, et al. Resistance 
of infant leukemia with MLL rearrangement to tumor necrosis factor- 
related apoptosis-inducing ligand: a possible mechanism for poor sensi-
tivity to antitumor immunity. Leukemia (2006) 20:2119–29. doi:10.1038/ 
sj.leu.2404429 
88. Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I, et  al. 
Combined effects of the two reciprocal t(4,11) fusion proteins MLL.AF4 and 
AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth 
transformation. Oncogene (2007) 26:3352–63. doi:10.1038/sj.onc.1210125 
89. Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly 
AD, et  al. Abundant anti-apoptotic BCL-2 is a molecular target in 
leukaemias with t(4,11) translocation. Br J Haematol (2008) 141:827–39. 
doi:10.1111/j.1365-2141.2008.07100.x 
90. Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, 
Krivtsov AV, et  al. EVI1 is critical for the pathogenesis of a subset of 
MLL-AF9-rearranged AMLs. Blood (2012) 119:5838–49. doi:10.1182/
blood-2011-11-393827 
91. Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, et  al. 
Cell of origin determines clinically relevant subtypes of MLL-rearranged 
AML. Leukemia (2013) 27:852–60. doi:10.1038/leu.2012.363 
92. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, et al. 
MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through 
H3K79 methylation and are sensitive to the BCL-2-specific antagonist 
ABT-199. Cell Rep (2015) 13:2715–27. doi:10.1016/j.celrep.2015.12.003 
93. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. 
The 2016 revision to the World Health Organization classification of myeloid 
neoplasms and acute leukemia. Blood (2016) 127:2391–405. doi:10.1182/
blood-2016-03-643544 
94. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu 
Rev Pathol (2012) 7:283–301. doi:10.1146/annurev-pathol-011811-132434 
95. Super HJG, McCabe NR, Thirman MJ, Larson RA, LeBeau MM, Pederson-
Bjergaard J, et al. Rearrangements of the MLL gene in therapy-related acute 
myeloid leukemia in patients previously treated with agents targeting DNA-
topoisomerase II. Blood (1993) 82(12):3705–11. 
96. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-
Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL 
rearrangements following DNA topoisomerase II inhibitors, an increasing 
problem: report on two new cases and review of the literature since 
1992. Br J Haematol (2001) 114:539–43. doi:10.1046/j.1365-2141.2001. 
03000.x 
97. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, 
et al. Improved outcome with hematopoietic stem cell transplantation in a 
poor progenostic subgroup of infants with mixed-lineage-leukemia (MLL)-
rearranged acute lymphoblastic leukemia: results from the Interfant-99 
study. Blood (2010) 116(15):2644–50. doi:10.1182/blood-2010-03-273532 
98. Blanco JG, Dervieux T, Edick MJ, Mehta PK, Rubnitz JE, Shurtleff S, et al. 
Molecular emergence of acute myeloid leukemia during treatment for acute 
lymphoblastic leukemia. Proc Natl Acad Sci U S A (2001) 98(18):10338–43. 
doi:10.1073/pnas.181199898 
99. Chowdhury T, Brady HJM. Insights from clinical studies into the role of 
the MLL gene in infant and childhood leukemia. Blood Cells Mol Dis (2008) 
40(2):192–9. doi:10.1016/j.bcmd.2007.07.005 
100. Felix CA. Secondary leukemias induced by topoisomerase-targeted 
drugs. Biochim Biophys Acta (1998) 1400:233–55. doi:10.1016/S0167-4781 
(98)00139-0 
101. Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood 
Cancer (2007) 49:1070–3. doi:10.1002/pbc.21352 
102. Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, et al. 
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with 
or without an MLL gene rearrangement, with emphasis on late effects: a 
final report of two consecutive studies, MLL96 and MLL98, of the Japan 
Infant Leukemia Study Group. Leukemia (2007) 21:2258–63. doi:10.1038/
sj.leu.2404903 
103. Tauchi H, Tomizawa D, Eguchi M, Eguchi-Ishimae M, Koh K, Hirayama M, 
et al. Clinical features and outcome of MLL gene rearranged acute lympho-
blastic leukemia in infants with additional chromosomal abnormalities other 
than 11q23 translocation. Leuk Res (2008) 32(10):1523–9. doi:10.1016/j.
leukres.2008.03.018 
18
Winters and Bernt MLL—An Update
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 4
104. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema 
NA, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in 
infants: report on CCG 1953 from the Children’s Oncology Group. Blood 
(2006) 108:441–51. doi:10.1182/blood-2005-07-3011 
105. Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, et al. 
The clinical characteristics, therapy and outcome of 85 adults with acute lym-
phoblastic leukemia and t(4,11)(q21,q23)/MLL-AFF1 prospectively treated 
in the UKALLXII/ECOG2993 trial. Haematologica (2013) 98(6):945–52. 
doi:10.3324/haematol.2012.081877 
106. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, 
Loonen AH, van Wering ER, et  al. In vitro drug-resistance profile in 
infant acute lymphoblastic leukemia in relation to age, MLL rearrange-
ments and immunophenotype. Leukemia (2004) 18(3):521–9. doi:10.1038/
sj.leu.2403253 
107. Stam RW, den Boer ML, Meijerink JPP, Ebus MEG, Peters GJ, Noordhuis 
P, et  al. Differential mRNA expression of Ara-C-metabolizing enzymes 
explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblas-
tic leukemia. Blood (2003) 101(4):1270–6. doi:10.1182/blood-2002-05-1600 
108. Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et  al. 
Acquisition of a CD19-negative myeloid phenotype allows immune escape 
of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood (2016) 
127:2406–10. doi:10.1182/blood-2015-08-665547 
109. Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged 
infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 
(2016) 63:1113–5. doi:10.1002/pbc.25953 
110. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, 
et al. The 2008 revision of the World Health Organization (WHO) classi-
fication of myeloid neoplasms and acute leukemia: rationale and important 
changes. Blood (2009) 114:937–51. doi:10.1182/blood-2009-03-209262 
111. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS, et  al. 
Microenvironment determines lineage fate in a human model of MLL-AF9 
leukemia. Cancer Cell (2008) 13:483–95. doi:10.1016/j.ccr.2008.04.020 
112. Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, et al. The MLL 
partial tandem duplication: evidence for recessive gain-of-function in acute 
myeloid leukemia identifies a novel patient subgroup for molecular-targeted 
therapy. Blood (2005) 106(1):345–52. doi:10.1182/blood-2005-01-0204 
113. Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem 
duplication in acute myeloid leukaemia. Br J Haematol (2006) 135:438–49. 
doi:10.1111/j.1365-2141.2006.06301.x 
114. Dohner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF, et  al. 
Prognostic significance of partial tandem duplications of the MLL gene in 
adult patients 16 to 60 years old with acute myeloid leukemia and normal 
cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. 
J Clin Oncol (2002) 20(15):3254–61. doi:10.1200/JCO.2002.09.088 
115. Reichel M, Gillert E, Angermuller S, Hensel JP, Heidel F, Lode M, et  al. 
Biased distribution of chromosomal breakpoints involving the MLL gene 
in infants versus children and adults with t(4,11) ALL. Oncogene (2001) 
20:2900–7. doi:10.1038/sj.onc.1204401 
116. Zhang Y, Rowley JD. Chromatin structural elements and chromosomal 
translocations in leukemia. DNA Repair (Amst) (2006) 5(9–10):1282–97. 
doi:10.1016/j.dnarep.2006.05.020 
117. Broeker PLS, Super HG, Thirman MJ, Pomykala H, Yonebayashi Y, Tanabe 
S, et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster 
region in de novo acute leukemia and in treatment-related acute myeloid 
leukemia: correlation with scaffold attachment regions and topoisomerase 
II consensus binding sites. Blood (1996) 87(5):1912–22. 
118. Scharf S, Zech J, Bursen A, Schraets D, Oliver PL, Kliem S, et al. Transcription 
linked to recombination: a gene-internal promoter coincides with the recom-
bination hot spot II of the human MLL gene. Oncogene (2007) 26:1361–71. 
doi:10.1038/sj.onc.1209948 
119. Betti CJ, Villalobos MJ, Jiang Q, Cline E, Diaz MO, Loredo G, et al. Cleavage 
of the MLL gene by activators of apoptosis is independent of topoisomerase 
II activity. Leukemia (2005) 19:2289–95. doi:10.1038/sj.leu.2403966 
120. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids 
induce cleavage in the MLL gene and may contribute to infant leukemia. 
Proc Natl Acad Sci U S A (2000) 97(9):4790–5. doi:10.1073/pnas.070061297 
121. Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, 
et  al. Transplacental chemical exposure and risk of infant leukemia with 
MLL gene fusion. Cancer Res (2001) 61:2542–6. 
122. Khosrovani SB, Janssen J, Maas LM, Godschalk RWL, Nijhuis JG, van 
Schooten FJ. Dietary flavonoids induce MLL translocations in primary 
human CD34+ cells. Carcinogenesis (2007) 28(8):1703–9. doi:10.1093/
carcin/bgm102 
123. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: 
lessons in natural history. Blood (2003) 102(7):2321–33. doi:10.1182/
blood-2002-12-3817 
124. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, et al. In 
utero rearrangements in the trithorax-related oncogene in infant leukaemias. 
Nature (1993) 363:358–60. doi:10.1038/363358a0 
125. Valentine MC, Linabery AM, Chasnoff S, Hughes AE, Mallaney C, Sanchez 
N, et al. Excess congenital non-synonymous variation in leukemia-associ-
ated genes in MLL-infant leukemia: a Children’s Oncology Group report. 
Leukemia (2014) 28:1235–41. doi:10.1038/leu.2013.367 
126. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, 
et  al. A treatment protocol for infants younger than 1 year with acute 
lymphoblastic leukaemia (Interfant-99): an observational study and a 
multicentre randomised trial. Lancet (2007) 370:240–50. doi:10.1016/
S0140-6736(07)61126-X 
127. Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, et al. 
Intensified chemotherapy without Sct in Infant All: results from COG P9407 
(cohort 3). Pediatr Blood Cancer (2015) 62:419–26. doi:10.1002/pbc.25322 
128. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, 
et  al. Treatment outcome and prognostic factors for infants with acute 
lymphoblastic leukemia treated on two consecutive trials of the Children’s 
Cancer Group. J Clin Oncol (1999) 17:445–55. 
129. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, 
et  al. Outcome of treatment in childhood acute lymphoblastic leukaemia 
with rearrangements of the 11q23 chromosomal region. Lancet (2002) 
359:1909–15. doi:10.1016/S0140-6736(02)08782-2 
130. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. New 
Engl J Med (2015) 373:1541–52. doi:10.1056/NEJMra1400972 
131. Jabbour E, O’Brien S, Konopleva M, Kantarjian H. New insights into the 
pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 
(2015) 121:2517–28. doi:10.1002/cncr.29383 
132. Rubnitz JE, Raimondi SC, Tong X, Srivastava DK, Razzouk BI, Shurtleff SA, 
et al. Favorable impact of the t(9,11) in childhood acute myeloid leukemia. 
J Clin Oncol (2002) 20:2302–9. doi:10.1200/JCO.2002.08.400 
133. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, 
Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-
rearranged acute myeloid leukemia: results of an international retrospective 
study. Blood (2009) 114:2489–96. doi:10.1182/blood-2009-04-215152 
134. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. 
Collaborative efforts driving progress in pediatric acute myeloid leukemia. 
J Clin Oncol (2015) 33:2949–62. doi:10.1200/JCO.2015.62.8289 
135. Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, et al. 
Adult de novo acute myeloid leukemia with t(6,11)(q27,q23): results from 
Cancer and Leukemia Group B Study 8461 and review of the literature. 
Cancer (2004) 101:1420–7. doi:10.1002/cncr.20489 
136. Emerenciano M, Meyer C, Mansur MB, Marschalek R, Pombo-de-Oliveira 
MS. Brazilian Collaborative Study Group of Infant Acute Leukaemia. The 
distribution of MLL breakpoints correlates with outcome in infant acute 
leukaemia. Br J Haematol (2013) 161:224–36. doi:10.1111/bjh.12250 
137. Marschalek R. Systematic classification of mixed-lineage leukemia fusion 
partners predicts additional cancer pathways. Ann Lab Med (2016) 
36:85–100. doi:10.3343/alm.2016.36.2.85 
138. Hale GA, Heslop HE, Bowman LC, Rochester RA, Pui CH, Brenner MK, 
et  al. Bone marrow transplantation for therapy-induced acute myeloid 
leukemia in children with previous lymphoid malignancies. Bone Marrow 
Transplant (1999) 24:735–9. doi:10.1038/sj.bmt.1701962 
139. Tomizawa D, Koh K, Hirayama M, Miyamura T, Hatanaka M, Saikawa Y, 
et  al. Outcome of recurrent or refractory acute lymphoblastic leukemia 
in infants with MLL gene rearrangements: a report from the Japan Infant 
Leukemia Study Group. Pediatr Blood Cancer (2009) 52:808–13. doi:10.1002/
pbc.21975 
140. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. 
Allogeneic transplantation for therapy-related myelodysplastic syndrome 
and acute myeloid leukemia. Blood (2010) 115:1850–7. doi:10.1182/
blood-2009-10-249128 
19
Winters and Bernt MLL—An Update
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 4
141. Finke J, Schmoor C, Bertz H, Marks R, Wasch R, Zeiser R, et  al. Long-
term follow-up of therapy-related myelodysplasia and AML patients treated 
with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 
(2016) 51:771–7. doi:10.1038/bmt.2015.338 
142. Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M, et  al. 
Analysis of the role of hematopoietic stem-cell transplantation in infants 
with acute lymphoblastic leukemia in first remission and MLL gene rear-
rangements: a report from the Children’s Oncology Group. J Clin Oncol 
(2011) 29:214–22. doi:10.1200/JCO.2009.26.8938 
143. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, 
et  al. Clinical heterogeneity in childhood acute lymphoblastic leukemia 
with 11q23 rearrangements. Leukemia (2003) 17:700–6. doi:10.1038/
sj.leu.2402883 
144. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment 
of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 
1987–1999. Br J Haematol (2002) 117:306–14. doi:10.1046/j.1365-2141. 
2002.03442.x 
145. van der Velden VHJ, Corral L, Valsecchi MG, Jansen MWJC, De Lorenzo 
P, Cazzaniga G, et al. Prognostic significance of minimal residual disease in 
infants with acute lymphoblastic leukemia treated within the Interfant-99 
protocol. Leukemia (2009) 23:1073–9. doi:10.1038/leu.2009.17 
146. van der Linden MH, Valsecchi MG, De Lorenzo P, Moricke A, Janka G, 
Leblanc TM, et  al. Outcome of congenital acute lymphoblastic leukemia 
treated on the Interfant-99 protocol. Blood (2009) 114:3764–8. doi:10.1182/
blood-2009-02-204214 
147. Annesley CE, Brown P. The biology and targeting of FLT3 in pediatric 
leukemia. Front Oncol (2014) 4:263. doi:10.3389/fonc.2014.00263 
148. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa 
TK, et  al. Prevalence and prognostic significance of Flt3 internal tandem 
duplication in pediatric acute myeloid leukemia. Blood (2001) 97:89–94. 
doi:10.1182/blood.V97.1.89 
149. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer 
ML, et  al. Inhibition of FLT3 in MLL: validation of a therapeutic target 
identified by gene expression based classification. Cancer Cell (2003) 
3:173–83. doi:10.1016/S1535-6108(03)00003-5 
150. Stam RW, Den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo 
HB, et  al. Targeting FLT3 in primary MLL-gene-rearranged infant 
acute lymphoblastic leukemia. Blood (2005) 106:2484–90. doi:10.1182/
blood-2004-09-3667 
151. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 
inhibition selectively kills childhood acute lymphoblastic leukemia cells 
with high levels of FLT3 expression. Blood (2005) 105:812–20. doi:10.1182/
blood-2004-06-2498 
152. Chillon MC, Gomez-Casares MT, Lopez-Jorge CE, Rodriguez-Medina 
C, Molines A, Sarasquete ME, et  al. Prognostic significance of FLT3 
mutational status and expression levels in MLL-AF4+ and MLL-germline 
acute lymphoblastic leukemia. Leukemia (2012) 26:2360–6. doi:10.1038/leu. 
2012.161 
153. Prelle C, Bursen A, Dingermann T, Marschalek R. Secondary mutations 
in t(4,11) leukemia patients. Leukemia (2013) 27:1425–7. doi:10.1038/
leu.2012.365 
154. Andersson AK, Ma J, Wang J, Chen X, Larson Gedman A, Dang J, et  al. 
The landscape of somatic mutations in infant MLL-rearranged acute lym-
phoblastic leukemias. Nat Genet (2015) 47(4):330–7. doi:10.1038/ng.3230 
155. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, et  al. 
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: devel-
opment of a model for rapid therapeutic assessment. Leukemia (2008) 
22:66–77. doi:10.1038/sj.leu.2404951 
156. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, Den Boer ML, Pieters 
R. Prognostic significance of high-level FLT3 expression in MLL-rearranged 
infant acute lymphoblastic leukemia. Blood (2007) 110(7):2774–5. 
doi:10.1182/blood-2007-05-091934 
157. Brown P, Levis M, McIntyre E, Griesemer M, Small D. Combinations of 
the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant 
and childhood MLL-rearranged ALL cells in a sequence-dependent manner. 
Leukemia (2006) 20:1368–76. doi:10.1038/sj.leu.2404277 
158. Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, et al. A phase 
I study of quizartinib combined with chemotherapy in relapsed childhood 
leukemia: a Therapeutic Advances in Childhood Leukemia & Lymphoma 
(TACL) study. Clin Cancer Res (2016) 22:4014–22. doi:10.1158/1078-0432.
CCR-15-1998 
159. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli 
B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the 
treatment of acute myeloid leukemia (AML). Blood (2009) 114:2984–92. 
doi:10.1182/blood-2009-05-222034 
160. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Dohner H, Dohner K, 
Schittenhelm MM. Quizartinib (AC220) is a potent second generation class 
III tyrosine kinase inhibitor that displays a distinct inhibition profile against 
mutant-FLT3, -PDGFRA, and –KIT isoforms. Mol Cancer (2013) 12:19. 
doi:10.1186/1476-4598-12-19 
161. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an 
expanding army attacking a unique target. Chem Biol (2012) 19:99–115. 
doi:10.1016/j.chembiol.2012.01.003 
162. Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, 
et  al. Proteasome inhibitors evoke latent tumor suppression programs in 
pro-B MLL leukemias through MLL-AF4. Cancer Cell (2014) 25:530–42. 
doi:10.1016/j.ccr.2014.03.008 
163. Xue K, Song J, Yang Y, Li Z, Wu C, Jin J, et  al. PAX5 promotes pre-B 
cell proliferation by regulating the expression of pre-B cell receptor and 
its downstream signaling. Mol Immunol (2016) 73:1–9. doi:10.1016/j.
molimm.2016.03.007 
164. Koss C, Nance S, Connelly M, Ma J, Shelat A, Cotton A, et  al. Targeted 
inhibition of the MLL transcriptional complex by proteasome inhibitors 
elicits a high response rate in relapsed/refractory MLL rearranged leukemia. 
Poster Abstract, American Society of Hematology Annual Meeting. San 
Francisco (2014).
165. Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, et  al. 
Systematic chemical and molecular profiling of MLL-rearranged infant 
acute leukemia reveals efficacy of romidepsin. Leukemia (2017) 31(1):40–50. 
doi:10.1038/leu.2016.165 
166. McGinty RK, Kim J, Chatterjee C, Roeder RG, Muir TW. Chemically 
ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal 
methylation. Nature (2008) 453:812–9. doi:10.1038/nature06906 
167. Wang E, Kawaoka S, Yu M, Shi J, Ni T, Yang W, et al. Histone H2B ubiquitin 
ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci 
U S A (2013) 110(10):3901–6. doi:10.1073/pnas.1301045110 
168. Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SHK, et al. 
Epigenetic roles of MLL oncoproteins are dependent on NF-kB. Cancer Cell 
(2013) 24:423–37. doi:10.1016/j.ccr.2013.08.019 
169. Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, et  al. 
Positive feedback between NF-kappaB and TNF-alpha promotes leukemia- 
initiating cell capacity. J Clin Invest (2014) 124:528–42. doi:10.1172/
JCI68101 
170. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to suscep-
tibility of tumor and other diseases. Histol Histopathol (2007) 22:1387–98. 
171. Tonelli R, Sartini R, Fronza R, Freccero F, Franzoni M, Dongiovanni D, 
et  al. G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition 
in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 
independent. Leukemia (2006) 20:1307–10. doi:10.1038/sj.leu.2404221 
172. Stumpel DJPM, Schneider P, Seslija L, Osaki H, Williams O, Pieters R, 
et  al. Connectivity mapping identifies HDAC inhibitors for the treatment 
of t(4,11)-positive infant acute lympoblastic leukemia. Leukemia (2012) 
26:682–92. doi:10.1038/leu.2011.278 
173. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, et al. Epigenetic 
reprogramming reverses the relapse-specific gene expression signature and 
restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 
(2012) 119(22):5201–10. doi:10.1182/blood-2012-01-401687 
174. Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, et  al. 
Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option 
for B-ALL. Clin Cancer Res (2015) 21(10):2348–58. doi:10.1158/1078-0432.
CCR-14-1290 
175. Moreno DA, Scrideli CA, Cortez MAA, de Paula Queiroz R, Valera ET, 
da Silva Silveira V, et  al. Differential expression of HDAC3, HDAC7 
and HDAC9 is associated with prognosis and survival in childhood 
acute lymphoblastic leukaemia. Br J Haematol (2010) 150:665–73. 
doi:10.1111/j.1365-2141.2010.08301.x 
176. Tao YF, Pang L, Du XJ, Sun LC, Hu SY, Lu J, et al. Differential mRNA expres-
sion levels of human histone-modifying enzymes in normal karyotype B cell 
20
Winters and Bernt MLL—An Update
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 4
pediatric acute lymphoblastic leukemia. Int J Mol Sci (2013) 14(2):3376–94. 
doi:10.3390/ijms14023376 
177. Gruhn B, Naumann T, Gruner D, Walther M, Wittig S, Becker S, et  al. 
The expression of histone deacetylase 4 is associated with prednisone 
poor-response in childhood acute lymphoblastic leukemia. Leuk Res (2013) 
37(10):1200–7. doi:10.1016/j.leukres.2013.07.016 
178. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C, 
et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S 
progression. Genes Dev (2010) 24:455–69. doi:10.1101/gad.552310 
179. Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X, et  al. Loss of 
TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and 
results in a glucocorticoid resistance in a B-lymphoblastic leukemia model. 
J Biol Chem (2014) 289(30):20502–15. doi:10.1074/jbc.M114.569889 
180. Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth 
M, et  al. Functional-genetic dissection of HDAC dependencies in mouse 
lymphoid and myeloid malignancies. Blood (2015) 126(21):2392–403. 
doi:10.1182/blood-2015-03-632984 
181. Ahmad K, Katryniok C, Scholz B, Merkens J, Loscher D, Marschalek R, 
et al. Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 
by activation of wild-type MLL. Oncogenesis (2014) 3:e127. doi:10.1038/
oncsis.2014.39 
182. Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince 
HM. MLL-aberrant leukemia: complete cytogenetic remission following 
treatment with a histone deacetylase inhibitor (HDACi). Ann Hematol 
(2011) 90:847–9. doi:10.1007/s00277-010-1099-6 
183. Stumpel DJPM, Schneider P, van Roon EHJ, Boer JM, de Lorenzo P, Valsecchi 
MG, et al. Specific promoter methylation identifies different subgroups of 
MLL-rearranged infant acute lymphoblastic leukemia, influences clinical 
outcome, and provides therapeutic options. Blood (2009) 114:5490–8. 
doi:10.1182/blood-2009-06-227660 
184. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, et  al. 
Promoter hypermethylation in MLL-r infant acute lymphoblastic leuke-
mia: biology and therapeutic targeting. Blood (2010) 115(23):4798–809. 
doi:10.1182/blood-2009-09-243634 
185. Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, 
Patnaik MM. Targeting epigenetic pathways in acute myeloid leukemia and 
myelodysplastic syndrome: a systematic review of hypomethylating agents 
trials. Clin Epigenetics (2016) 8:68–76. doi:10.1186/s13148-016-0233-2 
186. Lubecka-Pietruszewska K, Kaufman-Szymczyk A, Stefanska B, Cebula-
Obrzut B, Smolewski P, Fabianowska-Majewska K. Clofarabine, a novel 
adenosine analogue, reactivates DNA methylation-silenced tumor suppres-
sor genes and inhibits cell growth in breast cancer cells. Eur J Pharmacol 
(2014) 723:276–87. doi:10.1016/j.ejphar.2013.11.021 
187. Wyczechowska D, Fabianowska-Majewska K. The effects of cladribine and 
fludarabine on DNA methylation in K562 cells. Biochem Pharmacol (2003) 
65(2):219–25. doi:10.1016/S0006-2952(02)01486-7 
188. Stumpel DJPM, Schneider P, Pieters R, Stam RW. The potential of clofarabine 
in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer 
(2015) 51:2008–21. doi:10.1016/j.ejca.2015.06.117 
189. Stackelberg AV, Locatelli F, Zugmaier G, Handgretinger R, Trippet TM, 
Rizzari C, et al. Phase I/phaseII study of blinatumomab in pediatric patients 
with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol (2016) 
34(36):4381–9.
190. Driessen EMC, van Roon EHJ, Spijkers-Hagelstein JAP, Schneider P, de 
Lorenzo P, Valsecchi MG, et al. Frequencies and prognostic impact of RAS 
mutations in MLL-rearranged acute lymphoblastic leukemia in infants. 
Haematologica (2013) 98:937–44. doi:10.3324/haematol.2012.067983 
191. Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, et al. Acute myeloid 
leukemia with t(9;11)(p21-22;q23): common properties of dysregulated 
Ras pathway signaling and genomic progression characterize de novo and 
therapy-related cases. Am J Clin Pathol (2010) 133:686–93. doi:10.1309/
AJCPGII1TT4NYOGI 
192. Emerenciano M, Barbosa TC, de Almeida Lopes B, Meyer C, Marschalek R, 
Pombo-de-Oliveira MS. Subclonality and prenatal origin of RAS mutations 
in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia. Br 
J Haematol (2015) 170:268–87. doi:10.1111/bjh.13279 
193. Lavallee VP, Baccelli I, Krosl J, Wilhelm B, Barabe F, Gendron P, et  al. 
The transcriptomic landscape and directed chemical interrogation of 
MLL-rearranged acute myeloid leukemias. Nat Genet (2015) 47(9):1030–7. 
doi:10.1038/ng.3371 
194. Kerstjens M, Driessen EMC, Willekes M, Pinhancos SS, Schneider P, 
Pieters R, et  al. MEK inhibition is a promising therapeutic strategy for 
MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS 
mutations. Oncotarget (2016). doi:10.18632/oncotarget.11730 
195. Kampen KR, Elst A, Mahmud H, Scherpen FJG, Diks SH, Peppelenbosch 
MP, et  al. Insights in dynamic kinome reprogramming as a consequence 
of MEK inhibition in MLL-rearranged AML. Leukemia (2014) 28:589–99. 
doi:10.1038/leu.2013.342 
196. Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S, et  al. 
MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS 
activation in myeloid leukemia. Blood (2014) 124(2):263–72. doi:10.1182/
blood-2013-09-525741 
197. Chang MJ, Wu H, Achille NJ, Reisenauer MR, Chou CW, Zeleznik-Le 
NJ, et  al. Histone H3 lysine 79 methyltransferase Dot1 is required for 
immortalization by MLL oncogenes. Cancer Res (2010) 70(24):10234–42. 
doi:10.1158/0008-5472.CAN-10-3294 
198. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-
rearranged leukemia is dependent on aberrant H3K79 methylation by 
DOT1L. Cancer Cell (2011) 20:66–78. doi:10.1016/j.ccr.2011.06.010 
199. Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. Requirement for Dot1l 
in murine postnatal hematopoiesis and leukemogenesis by MLL translo-
cation. Blood (2011) 117(18):4759–68. doi:10.1182/blood-2010-12-327668 
200. Nguyen AT, Taranova O, He J, Zhang Y. Dot1l, the H3K79 methyltrans-
ferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 
117(25):6912–22. doi:10.1182/blood-2011-02-334359 
201. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et  al. 
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. 
Cancer Cell (2008) 14:355–68. doi:10.1016/j.ccr.2008.10.001 
202. Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, et al. DOT1L 
inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene 
expression in MLL-rearranged leukemia. Nat Med (2015) 21(4):335–43. 
doi:10.1038/nm.3832 
203. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-
Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion 
leukemia. Blood (2013) 122(6):1017–25. doi:10.1182/blood-2013-04-497644 
204. Klaus CR, Iwanowicz D, Johnston D, Campbell CA, Smith JJ, Moyer MP, 
et  al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative 
activity in combination with standard of care drugs and hypomethylating 
agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther (2014) 
350:646–56. doi:10.1124/jpet.114.214577 
205. Luo M, Wang H, Zou Y, Zhang S, Xiao J, Jiang G, et  al. Identification 
of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking 
screening and molecular dynamics simulation. J Mol Graph Model (2016) 
68:128–39. doi:10.1016/j.jmgm.2016.06.011 
206. Shukla N, O’Brien MM, Silverman LB, Pauly M, Wetmore C, Loh ML, 
et  al. Preliminary report of the phase 1 study of the DOT1L inhibitor, 
Pinometostat, EPZ-5676, in children with relapsed or refractory MLL-r 
acute leukemia: safety, exposure and target inhibition. Blood (2015) 
126:3792. 
207. Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Jongen-
Lavrencic M, et al. A phase 1 study of the DOT1L inhibitor, Pinometostat 
(EPZ-5676), in adults with relapsed or refractory leukemia: safety, clinical 
activity, exposure and target inhibition. Blood (2015) 126:2547. 
208. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. 
AFF4, a component of the ELL-P-TEFb elongation complex and a shared 
subunit of MLL chimeras, can link transcription elongation to leukemia. 
Mol Cell (2010) 37:429–37. doi:10.1016/j.molcel.2010.01.026 
209. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, 
Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective 
treatment for MLL-fusion leukemia. Nature (2011) 478:529–33. doi:10.1038/
nature10509 
210. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi 
screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. 
Nature (2011) 478:524–8. doi:10.1038/nature10334 
211. Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, 
et  al. Generation of a selective small molecule inhibitor of the CBP/p300 
21
Winters and Bernt MLL—An Update
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 4
bromodomain for leukemia therapy. Cancer Res (2015) 75(23):5106–19. 
doi:10.1158/0008-5472.CAN-15-0236 
212. Gilan O, Lam EYN, Becher I, Lugo D, Cannizzaro E, Joberty G, et  al. 
Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat 
Struct Mol Biol (2016) 23(7):673–81. doi:10.1038/nsmb.3249 
213. Garcia-Cuellar MP, Buttner C, Bartenhagen C, Dugas M, Slany RK. 
Leukemogenic MLL-ENL fusions induce alternative chromatin states to 
drive a functionally dichotomous group of target genes. Cell Rep (2016) 
15:310–22. doi:10.1016/j.celrep.2016.03.018 
214. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone 
demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leuke-
mia stem cells. Cancer Cell (2012) 21:473–87. doi:10.1016/j.ccr.2012.03.014 
215. Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, et  al. The poly-
comb complex PRC2 supports aberrant self-renewal in a mouse model 
of MLL-AF9,NrasG12D acute myeloid leukemia. Oncogene (2013) 32:930–8. 
doi:10.1038/onc.2012.110 
216. Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, et al. Pharmacological inhibition 
of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol 
(2016) 9:24–36. doi:10.1186/s13045-016-0252-7 
217. Smith LL, Yeung J, Zeisig BB, Popov N, Huijbers I, Barnes J, et al. Functional 
crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal 
hematopoietic and leukemic stem cells. Cell Stem Cell (2011) 8:649–62. 
doi:10.1016/j.stem.2011.05.004 
218. Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, Iwama A. Bmi1 is 
essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 
(2011) 25:1335–43. doi:10.1038/leu.2011.85 
219. Rossi A, Ferrari KJ, Piunti A, Jammula S, Chiacchiera F, Mazzarella L, et al. 
Maintenance of leukemic cell identity by the activity of the Polycomb complex 
PRC1 in mice. Sci Adv (2016) 2(10):e1600972. doi:10.1126/sciadv.1600972 
220. Maethner E, Garcia-Cuellar MP, Breitinger C, Takacova S, Divoky V, Hess 
JL, et  al. MLL-ENL inhibits polycomb repressive complex 1 to achieve 
efficient transformation of hematopoietic cells. Cell Rep (2013) 3:1553–66. 
doi:10.1016/j.celrep.2013.03.038 
221. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, et al. Polycomb 
repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci 
U S A (2012) 109(13):5028–33. doi:10.1073/pnas.1202258109 
222. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted 
disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat 
Chem Biol (2013) 9:643–50. doi:10.1038/nchembio.1331 
223. Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, et al. 
Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through 
Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine 
model. Exp Hematol (2015) 43:930–5. doi:10.1016/j.exphem.2015.06.005 
224. Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, 
et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem 
cell of mixed lineage leukemia fusion leukemia through upregulation of 
p16. Cancer Sci (2014) 105:512–9. doi:10.1111/cas.12386 
225. Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective 
inhibition of EZH2 and EZH1 enzymatic activity by a small molecule 
suppresses MLL-rearranged leukemia. Blood (2015) 125(2):346–57. 
doi:10.1182/blood-2014-06-581082 
226. Urtishak KA, Edwards AYZ, Wang LS, Hudome A, Robinson BW, Barrett JS, 
et al. Potent obatoclax cytotoxicity and activation of triple death mode killing 
across infant acute lymphoblastic leukemia. Blood (2013) 121:2689–703. 
doi:10.1182/blood-2012-04-425033 
227. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. 
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity 
while sparing platelets. Nat Med (2013) 19:202–8. doi:10.1038/nm.3048 
228. Souers AJ. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/
refractory non-Hodgkin lymphoma: responses observed in diffuse large 
B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Clin 
Adv Hematol Oncol (2014) 12(8 Suppl 16):18–9. 
229. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. 
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. 
N Engl J Med (2016) 374:311–22. doi:10.1056/NEJMoa1513257 
230. Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, 
et  al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity 
of MLL-rearranged leukemia. Blood (2016) 128(10):1382–95. doi:10.1182/
blood-2016-03-707414 
231. van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters 
R, et al. MLL fusion-driven activation of CDK6 potentiates proliferation in 
MLL-rearranged infant ALL. Cell Cycle (2014) 13(5):834–44. doi:10.4161/
cc.27757 
232. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, et  al. 
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 
(2014) 124(1):13–23. doi:10.1182/blood-2014-02-558114 
233. Maillard I, Chen YX, Friedman A, Yang Y, Tubbs AT, Shestova O, et  al. 
Menin regulates the function of hematopoietic stem cells and lymphoid 
progenitors. Blood (2009) 113:1661–9. doi:10.1182/blood-2009-01-135012 
234. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, 
et  al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion 
proteins in leukemia. Nat Chem Biol (2012) 8(3):277–84. doi:10.1038/
nchembio.773 
235. Borkin D, Pollock J, Kempinska K, Purohit T, Li X, Wen B, et al. Property 
focused structure-based optimization of small molecule inhibitors of the 
 protein-protein interaction between Menin and mixed-lineage leukemia 
(MLL). J Med Chem (2016) 59(3):892–913. doi:10.1021/acs.jmedchem. 
5b01305 
236. He S, Malik B, Borkin D, Miao H, Shukla S, Kempinska K, et  al. Menin-
MLL inhibitors block oncogenic transformation by MLL-fusion partners 
in a fusion partner-independent manner. Leukemia (2016) 30(2):508–13. 
doi:10.1038/leu.2015.144 
237. Xu Y, Yue L, Wang Y, Xing J, Chen Z, Shi Z, et  al. Discovery of novel 
inhibitors targeting the Menin-mixed lineage leukemia interface using 
pharmacophore- and docking-based virtual screening. J Chem Inf Model 
(2016) 56(9):1847–55. doi:10.1021/acs.jcim.6b00185 
238. Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, et  al. The 
CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in 
preclinical models of MLL-rearranged acute myeloid leukemia. Cancer Res 
(2016) 76(5):1158–69. doi:10.1158/0008-5472.CAN-15-1070 
Conflict of Interest Statement: KB: I hold two patents with respect to the DOT1L 
inhibitor discussed in this manuscript (pertaining to it’s use in leukemias with high 
MN1 expression, and pertaining to the role of MDR1 mediated drug resistance). 
Neither is directly relevant to the discussion in this review article. My husband 
has just accepted a job as a medical director at Janssen. His work will not involve 
any of the agents discussed in this review article. AW declare that the research 
was conducted in the absence of any commercial or financial relationships that 
could be construed as a potential conflict of interest.
Copyright © 2017 Winters and Bernt. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
